var title_f31_54_32608="Prone hip exam";
var content_f31_54_32608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Prone examination of the hip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the knees flexed to 90 degrees and both feet caused to \"fall outward,\" subtle asymmetry in internal rotation is readily appreciated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32608=[""].join("\n");
var outline_f31_54_32608=null;
var title_f31_54_32609="Sequestration aortogram II";
var content_f31_54_32609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right lower lobe intralobar sequestration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An aortogram demonstrates a splanchnic artery originating from the upper abdominal aorta, which supplies a large basilar sequestration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32609=[""].join("\n");
var outline_f31_54_32609=null;
var title_f31_54_32610="Lemon sign";
var content_f31_54_32610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The \"lemon\" sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The frontal bossing (arrows) typically termed the lemon sign is present in cases of open spina bifida.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32610=[""].join("\n");
var outline_f31_54_32610=null;
var title_f31_54_32611="Abdominal aortic aneurysm on three-dimensional imaging";
var content_f31_54_32611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm on three-dimensional imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The&nbsp;three-dimensional&nbsp;rendered CT images show a 5.2 cm infrarenal abdominal aortic aneurysm (between white arrows). The aneurysm originates 2.3 cm below the renal arteries and terminates 1.9 cm above the iliac bifurcation.",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32611=[""].join("\n");
var outline_f31_54_32611=null;
var title_f31_54_32612="Cyclizine: Drug information";
var content_f31_54_32612=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclizine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/29/44499?source=see_link\">",
"    see \"Cyclizine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bonine&reg; for Kids [OTC] [DSC];",
"     </li>",
"     <li>",
"      Cyclivert&reg; [OTC];",
"     </li>",
"     <li>",
"      Marezine&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Piperazine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Motion sickness (prophylaxis and treatment):",
"     </b>",
"     Oral: 50 mg taken 30 minutes before departure; may repeat in 4-6 hours if needed, up to 200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F155222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Motion sickness (prophylaxis and treatment):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6-11 years: 25 mg 1 hour before travel or at onset of symptoms, repeat dose every 6-8 hours (maximum: 3 tablets/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F155213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclivert&reg;: 25 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Marezine&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bonine&reg; for Kids: 25 mg [DSC] [scored; berry blast flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of nausea, vomiting, and vertigo associated with motion sickness",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F155230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Polyuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclizine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11450024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Prior to self medication (OTC use) patients with asthma, glaucoma, prostatic hyperplasia, or respiratory disease should consult healthcare provider. Consult healthcare provider prior to frequent or prolonged use. Do not exceed recommended dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F155209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14386658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An increased risk of birth defects following maternal cyclizine use has generally not been observed. Although cyclizine has been evaluated for the treatment of nausea and vomiting in pregnancy, it is not currently recommended for this indication (consult current guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14386660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Information specific to the use of cyclizine and breast-feeding has not been located. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cyclivert Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $37.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Marezine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (12): $4.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclizine FNA (NL);",
"     </li>",
"     <li>",
"      Echnatol (AT);",
"     </li>",
"     <li>",
"      Fortravel (AT);",
"     </li>",
"     <li>",
"      Liumpin (TW);",
"     </li>",
"     <li>",
"      Maremal (ES);",
"     </li>",
"     <li>",
"      Marzine (CH, DK, FI, IT, NL, NO, PK, SE);",
"     </li>",
"     <li>",
"      Nausicalm (NZ);",
"     </li>",
"     <li>",
"      Norizine (ZA);",
"     </li>",
"     <li>",
"      Valoid (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F155194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cyclizine is a piperazine derivative with properties of histamines. The precise mechanism of action in inhibiting the symptoms of motion sickness is not known. It may have effects directly on the labyrinthine apparatus and central actions on the labyrinthine apparatus and on the chemoreceptor trigger zone. Cyclizine exerts a central anticholinergic action.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13766219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 17 L/kg (range: 13-20 L/kg) (Walker, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; Undergoes demethylation to inactive metabolites (norcyclizine and norchlorcyclizine) (Paton, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Cyclizine: ~14 hours; Norcyclizine: ~24 hours; Norchlorcyclizine: ~6 days (Paton, 1985; Walker, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&lt;1% as unchanged drug) (Walker, 1996)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Paton DM and Webster DR, \"Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines),\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1985, 10(6):477-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/54/32612/abstract-text/2866055/pubmed\" id=\"2866055\" target=\"_blank\">",
"        2866055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker RB and Kanfer I, \"Pharmacokinetics of Cyclizine Following Intravenous Administration to Human Volunteers,\"",
"      <i>",
"       Eur J Pharm Sci",
"      </i>",
"      , 1996, 4(5):301-6.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8889 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32612=[""].join("\n");
var outline_f31_54_32612=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155210\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155232\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155212\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155222\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155213\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155203\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155191\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155204\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155230\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155206\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11450024\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299106\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155198\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155209\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14386658\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14386660\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323082\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539837\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155194\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13766219\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8889\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8889|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/29/44499?source=related_link\">",
"      Cyclizine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_54_32613="Danazol: Patient drug information";
var content_f31_54_32613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Danazol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"     see \"Danazol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/11/5301?source=see_link\">",
"     see \"Danazol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclomen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700719",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems, blood clots, stroke, or more pressure in your brain. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700271",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug if you are pregnant. A pregnancy test will be done to show that you are NOT pregnant before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work as well to prevent pregnancy. Use some other kind of birth control also like a condom when taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700313",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you get pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691844",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat fibrocystic breast disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling of the face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to danazol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of the following conditions: Blood clot, genital bleeding, porphyria, very bad heart disease, very bad kidney disease, or very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Raised pressure in the brain may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, a deep voice, facial hair, pimples, or period changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a pregnancy test before starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11715 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32613=[""].join("\n");
var outline_f31_54_32613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156636\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027128\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027130\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027129\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027134\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027135\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027137\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027132\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027133\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027138\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027139\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=related_link\">",
"      Danazol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/11/5301?source=related_link\">",
"      Danazol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_54_32614="Membranoproliferative glomerulonephritis: Recurrence after transplantation";
var content_f31_54_32614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Membranoproliferative glomerulonephritis: Recurrence after transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32614/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32614/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32614/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32614/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32614/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32614/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/54/32614/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN; also called mesangiocapillary or lobular glomerulonephritis) is an uncommon cause of glomerular disease that, in its idiopathic form, primarily occurs between the ages of 8 and 30. Three histologic forms of MPGN have been identified by electron microscopy: type I, II (also called dense deposit disease), and III. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the non-transplant setting, idiopathic MPGN type I is currently a rare overall cause of glomerulonephritis and a diagnosis of exclusion. Histologic findings of type I disease are not specific for idiopathic MPGN, since they are thought to reflect the deposition of circulating immune complexes. Among the most common secondary causes of type I disease in the non-transplant setting are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatitis C virus infection, with or without mixed cryoglobulinemia",
"     </li>",
"     <li>",
"      Mixed cryoglobulinemia not due to hepatitis C virus infection",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Hepatitis B virus infection",
"     </li>",
"     <li>",
"      Subacute bacterial (infective) endocarditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discussions concerning the interplay between these",
"    <span class=\"nowrap\">",
"     infections/diseases",
"    </span>",
"    and renal transplantation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44488?source=see_link\">",
"     \"Renal disease associated with hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39352?source=see_link\">",
"     \"End-stage renal disease due to lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both idiopathic type I (mesangial and subendothelial deposits) and the less common MPGN type II (dense-deposit disease) MPGN commonly recur after renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although these disorders have different sites of electron dense deposits, they are both associated with the other classic histologic changes of MPGN: increased glomerular cellularity and a double contour (tram-track) appearance of the glomerular basement membrane due to mesangial cell interposition and new basement membrane formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MPGN TYPE I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported rate of recurrent disease in idiopathic MPGN type I has usually ranged between 20 and 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/2-8\">",
"     2-8",
"    </a>",
"    ], although the incidence in children may be somewhat higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/9\">",
"     9",
"    </a>",
"    ]. Perhaps the best estimate of the incidence of graft loss due to recurrent MPGN type I was provided by a study of 1505 renal transplant recipients with a history of end-stage renal disease due to biopsy-proven glomerulonephritis, of whom 88 had MPGN type I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of allograft loss at 10 years due to recurrent MPGN type I was 14.4 percent (95 percent CI 7.6 to 26.4 percent), which was similar to that of recurrent focal segmental glomerulosclerosis. In an analysis of nearly 190,000 renal transplant patients in the United Network for Organ Sharing (UNOS) database, the incidence of allograft loss at 10 years due to recurrent MPGN type I was similarly 14.5 percent, which was higher than other glomerulonephritides combined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another analysis reported on disease recurrence in 32 patients with MPGN type I following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/12\">",
"     12",
"    </a>",
"    ]. The disease recurrence rate was 33 percent in 27 patients receiving a deceased donor kidney and 3 of 5 in living related allograft recipients. All patients with recurrent MPGN in this report presented with urine protein excretion of greater than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at a median of 20 months following transplantation (range 1.5 to 42 months). The mean duration of graft survival following the diagnosis of recurrent disease was 40 months.",
"   </p>",
"   <p>",
"    Little data exist concerning recurrent disease in a second allograft. In the study previously mentioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/12\">",
"     12",
"    </a>",
"    ], four of five patients receiving a second transplant after losing the initial allograft as a result of recurrent MPGN also experienced disease recurrence in the second allograft.",
"   </p>",
"   <p>",
"    However, these reported recurrence rates may represent an overestimate, since similar histologic changes can occur as part of chronic transplant rejection (transplant glomerulopathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/13\">",
"     13",
"    </a>",
"    ]. Nevertheless, findings on electron microscopy (such as the absence of immune complex deposition in transplant glomerulopathy) may help distinguish between these two disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with recurrent disease may remain asymptomatic, although the majority of patients with recurrent MPGN tend to present with proteinuria, hematuria and hypertension. Hypocomplementemia may be associated with recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]; however, disease recurrence can occur in the absence of this finding. The presence of serum monoclonal proteins may be associated with recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/16\">",
"     16",
"    </a>",
"    ], although some cases of MPGN that are associated with IgG deposits in the kidney may recur in the absence of circulating monoclonal IgG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interesting case report described a potential association between cytomegalovirus (CMV) and recurrent histologic findings of MPGN following transplantation in the absence of detectable virus within the allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no proven beneficial therapy for the treatment of recurrent idiopathic MPGN, although the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    may stabilize renal function, similar to its efficacy in primary MPGN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/7\">",
"     7",
"    </a>",
"    ]. The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is uncertain. Some investigators have found it to be ineffective in recurrent disease, while others have suggested that the rate of recurrence fell from 30 to 10 percent after the introduction of cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/19\">",
"     19",
"    </a>",
"    ]. There are also case reports describing successful treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or plasmapheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11152926\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT MPGN TYPE I",
"    </span>",
"    &nbsp;&mdash;&nbsp;While no specific treatment exists for the treatment of recurrent idiopathic MPGN, aggressive treatment using plasmapheresis and adjuvant immunosuppression may be warranted in the setting of rapidly worsening graft function or histologic findings suggestive of rapidly progressive disease.",
"   </p>",
"   <p>",
"    In the setting of stable graft function, especially associated with non-nephrotic range proteinuria, conservative management is generally preferred. This should include blood pressure control, the use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers along with a statin.",
"   </p>",
"   <p>",
"    The treatment of recurrent disease in the setting of active hepatitis C virus infection, including the use of interferon gamma, is somewhat controversial; however, it should be considered in appropriate candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/22\">",
"     22",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MPGN TYPE II (DENSE DEPOSIT DISEASE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPGN type II, also known as dense deposit disease, tends to recur more frequently than MPGN type I, ranging from 50 to 100 percent in various series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/3-5,8,9,23\">",
"     3-5,8,9,23",
"    </a>",
"    ]. Affected patients typically present within one year following transplantation with non-nephrotic range proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the findings in one report are inconsistent with this view. In this analysis, the type of MPGN was not associated with recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/24\">",
"     24",
"    </a>",
"    ]; instead, age at initial diagnosis as well as the presence of crescents in the native renal biopsy were independently associated with recurrence of disease in the allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Graft loss due to recurrent disease is thought to occur in only 10 to 20 percent of cases, although some centers have reported rates as high as 30 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ]. In the previously mentioned UNOS analysis, graft loss due to recurrent MPGN type II was 29.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/11\">",
"     11",
"    </a>",
"    ]. Conversely, the previously mentioned follow-up of 1505 transplant recipients with glomerulonephritis included 18 patients with MPGN type II, none of whom had evidence of graft loss secondary to recurrent disease at 10 years following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to those without MPGN type II, the overall unadjusted allograft survival in one analysis of pediatric transplant patients was significantly decreased, with a five-year graft survival of only 50 percent (versus 75 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/23\">",
"     23",
"    </a>",
"    ]; approximately 15 percent of recipients experienced graft loss secondary to recurrent disease. Five-year graft survival in living donor recipients with MPGN type II was markedly improved as compared to MPGN type II recipients of a deceased donor allograft (66 versus 34 percent). The previously mentioned UNOS analysis confirmed the poor outcomes among pediatric patients but found a much more favorable outcome with adults with MPGN type II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11152972\">",
"    <span class=\"h1\">",
"     TREATMENT OF MPGN TYPE II",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in type I disease, there is no known effective therapy, but a diagnosis of MPGN II should prompt screening for mutations in complement factor H (CFH), assays of complement activity, quantification of complement components, and testing for C3 nephritic factor (C3NeF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=see_link&amp;anchor=H12#H12\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Special diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of a wide variety of treatments for recurrent MPGN II has been reported. In one large retrospective study from the North American Pediatric database, reported interventions included plasmapheresis, substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , reduction in the dose or discontinuation of the calcineurin inhibitor, increase in the corticosteroid dose, or the administration of pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/23\">",
"     23",
"    </a>",
"    ]. Successful treatment of recurrent MPGN II has been described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    , an anti-C5 antibody that blocks C5a formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several treatment options should be considered if a disease-causing mutation or disease-associated variant of CFH is detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=see_link&amp;anchor=H15#H15\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MPGN TYPE III",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPGN type III is an immune complex disease which is similar to MPGN type I but with prominent subepithelial or intramembranous deposits and a complex disruption of the glomerular basement membrane. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    .) Little is known concerning recurrent disease among patients with MPGN type III who undergo renal transplantation. Two case reports have been reported of recurrent MPGN III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In the first case a 48 year old white patient with end-stage renal disease due to MPGN type III presented with hematuria and proteinuria 16 months after undergoing renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/29\">",
"     29",
"    </a>",
"    ]. Renal biopsy revealed recurrent MPGN type III and graft loss occurred seven years later. In a second case, a 57 year old white male received a one-haplotype living related transplant from his daughter. Sixteen months after transplantation he developed acute renal failure unresponsive to plasmapheresis and returned to dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A de novo case of MPGN III has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/31\">",
"     31",
"    </a>",
"    ]. In this report, the patient was a 57-year old white female with ESRD from biopsy proven",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    toxicity who developed MPGN III in her allograft six years after a renal transplant. Despite use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonists, vitamin D and immunosuppressives including corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , she progressed to end stage renal disease (ESRD) from MPGN III within four and a half years from the time of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DE NOVO MPGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, patients with a different primary disease will develop de novo MPGN in the allograft. One example is MPGN due to hepatitis C virus infection, a principal cause of MPGN and mixed cryoglobulinemia in native kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    may be useful in treating de novo MPGN in renal transplant recipients in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32614/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    .) A de novo case of MPGN III has been reported (see",
"    <a class=\"local\" href=\"#H4\">",
"     'MPGN type III'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent MPGN following transplantation is not an uncommon event, particularly with MPGN type II. While expected graft survival is decreased in the setting of recurrent MPGN, many grafts will continue to have adequate function and are eventually lost for reasons other than recurrent disease.",
"   </p>",
"   <p>",
"    Given the lack of a proven beneficial therapeutic intervention, the aggressiveness of treatment should match the aggressiveness of the disease process. The presence of hepatitis C and CMV virus should be evaluated and treated accordingly. There are no data to suggest that transplantation with a deceased donor rather than a living donor allograft has a favorable effect on overall graft survival by decreasing the likelihood of recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28234348\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Georges Saab, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/1\">",
"      Denton MD, Singh AK. Recurrent and de novo glomerulonephritis in the renal allograft. Semin Nephrol 2000; 20:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/2\">",
"      Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003; 18:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/3\">",
"      Kotanko P, Pusey CD, Levy JB. Recurrent glomerulonephritis following renal transplantation. Transplantation 1997; 63:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/4\">",
"      Mathew TH. Recurrence of disease following renal transplantation. Am J Kidney Dis 1988; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/5\">",
"      Cameron JS. Glomerulonephritis in renal transplants. Transplantation 1982; 34:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/6\">",
"      Curtis JJ, Wyatt RJ, Bhathena D, et al. Renal transplantation for patients with type I and type II membranoproliferative glomerulonephritis: serial complement and nephritic factor measurements and the problem of recurrence of disease. Am J Med 1979; 66:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/7\">",
"      Glicklich D, Matas AJ, Sablay LB, et al. Recurrent membranoproliferative glomerulonephritis type 1 in successive renal transplants. Am J Nephrol 1987; 7:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/8\">",
"      Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/9\">",
"      Habib R, Antignac C, Hinglais N, et al. Glomerular lesions in the transplanted kidney in children. Am J Kidney Dis 1987; 10:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/10\">",
"      Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/11\">",
"      Angelo JR, Bell CS, Braun MC. Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. Am J Kidney Dis 2011; 57:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/12\">",
"      Andresdottir MB, Assmann KJ, Hoitsma AJ, et al. Recurrence of type I membranoproliferative glomerulonephritis after renal transplantation: analysis of the incidence, risk factors, and impact on graft survival. Transplantation 1997; 63:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/13\">",
"      Cheigh JS, Mouradian J, Susin M, et al. Kidney transplant nephrotic syndrome: relationship between allograft histopathology and natural course. Kidney Int 1980; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/14\">",
"      Andresdottir MB, Assmann KJ, Koene RA, Wetzels JF. Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 1998; 32:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/15\">",
"      McLean RH, Geiger H, Burke B, et al. Recurrence of membranoproliferative glomerulonephritis following kidney transplantation. Serum complement component studies. Am J Med 1976; 60:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/16\">",
"      Lorenz EC, Sethi S, Leung N, et al. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 2010; 77:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/17\">",
"      Nasr SH, Sethi S, Cornell LD, et al. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol 2011; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/18\">",
"      Andresdottir MB, Assmann KJ, Hilbrands LB, Wetzels JF. Type I membranoproliferative glomerulonephritis in a renal allograft: A recurrence induced by a cytomegalovirus infection? Am J Kidney Dis 2000; 35:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/19\">",
"      Tomlanovich S, Vincenti F, Amend W, et al. Is cyclosporine effective in preventing recurrence of immune-mediated glomerular disease after renal transplantation? Transplant Proc 1988; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/20\">",
"      Lien YH, Scott K. Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. Am J Kidney Dis 2000; 35:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/21\">",
"      Muczynski KA. Plasmapheresis maintained renal function in an allograft with recurrent membranoproliferative glomerulonephritis type I. Am J Nephrol 1995; 15:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/22\">",
"      Zeman M, Campbell P, Bain VG. Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol 2006; 20:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/23\">",
"      Braun MC, Stablein DM, Hamiwka LA, et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005; 16:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/24\">",
"      Little MA, Dupont P, Campbell E, et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 2006; 69:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/25\">",
"      Eddy A, Sibley R, Mauer SM, Kim Y. Renal allograft failure due to recurrent dense intramembranous deposit disease. Clin Nephrol 1984; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/26\">",
"      Andresdottir MB, Assmann KJ, Hoitsma AJ, et al. Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome. Nephrol Dial Transplant 1999; 14:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/27\">",
"      Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/28\">",
"      McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/29\">",
"      Morales JM, Martinez MA, Mu&ntilde;oz de Bustillo E, et al. Recurrent type III membranoproliferative glomerulonephritis after kidney transplantation. Transplantation 1997; 63:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/30\">",
"      Ramesh Prasad GV, Shamy F, Zaltzman JS. Recurrence of type III membranoproliferative glomerulonephritis after renal transplantation. Clin Nephrol 2004; 61:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/31\">",
"      Java A, Gaut JP, Brennan DC. De novo membranoproliferative glomerulonephritis III in a renal transplant patient: case report and review of the literature. Transpl Int 2012; 25:e58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/32\">",
"      Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32614/abstract/33\">",
"      Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80:1560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7343 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32614=[""].join("\n");
var outline_f31_54_32614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MPGN TYPE I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11152926\">",
"      TREATMENT OF RECURRENT MPGN TYPE I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MPGN TYPE II (DENSE DEPOSIT DISEASE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11152972\">",
"      TREATMENT OF MPGN TYPE II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MPGN TYPE III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DE NOVO MPGN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28234348\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=related_link\">",
"      Dense deposit disease (membranoproliferative glomerulonephritis type II)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39352?source=related_link\">",
"      End-stage renal disease due to lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=related_link\">",
"      Renal disease associated with hepatitis C virus after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_54_32615="Contents: Urologic surgery";
var content_f31_54_32615=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Urologic surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Urologic surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Endourology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/57/29592\">",
"           Diagnostic cystourethroscopy for gynecologic conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/56/15242\">",
"           Placement and management of indwelling ureteral stents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inguinal hernia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/37/31321\">",
"           Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/0/11268\">",
"           Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/49/26393\">",
"           Inguinal and femoral hernia repair: Laparoscopic techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/15/9465\">",
"           Inguinal and femoral hernia repair: Open techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/52/34632\">",
"           Operative management of recurrent inguinal hernias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21561\">",
"           Overview of inguinal hernia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/20/29000\">",
"           Overview of treatment for inguinal and femoral hernias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/57/20373\">",
"           Sports-related groin pain or 'sports hernia'",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lower urinary tract disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/42/4776\">",
"           Acute bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/47/10999\">",
"           Acute complicated cystitis and pyelonephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/4/35912\">",
"           Acute urinary retention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/4/29766\">",
"           Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/34/35367\">",
"           Chemoprevention of bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/60/23496\">",
"           Chronic bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/14/29929\">",
"           Clinical presentation and diagnosis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/18/33061\">",
"           Clinical use of saw palmetto",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/23/31096\">",
"           Complications of intravesical BCG immunotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/9/33941\">",
"           Complications of urinary bladder catheters and preventive strategies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/39/23161\">",
"           Cystitis in patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/61/26586\">",
"           Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/19/34104\">",
"           Epidemiology and pathogenesis of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/21/40281\">",
"           Etiology and evaluation of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/47/29431\">",
"           Experimental systemic therapy of metastatic bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/10/22694\">",
"           Hematospermia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/43/19126\">",
"           Infectious causes of dysuria in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/39/5749\">",
"           Laparoscopic/robotic-assisted radical cystectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/1/11290\">",
"           Lower urinary tract symptoms in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/22/43369\">",
"           Management of interstitial cystitis/bladder pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/0/41992\">",
"           Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/29/40409\">",
"           Nonurothelial bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/44/2759\">",
"           Overview of the management of urothelial (transitional cell) bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/7/13432\">",
"           Overview of the treatment of testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/8/8330\">",
"           Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/53/27481\">",
"           Pathology of bladder neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/11/29873\">",
"           Patient information: Prostatitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/47/40697\">",
"           Placement and management of urinary bladder catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/6/11366\">",
"           Small cell carcinoma of the bladder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/7/40056\">",
"           Surgical and other invasive therapies of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/36/11849\">",
"           Surgical management and postoperative outcome of children with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/27/19897\">",
"           Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/11/40122\">",
"           Treatment of non-muscle-invasive bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/48/36617\">",
"           Treatment of urethral stricture disease in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/26/10664\">",
"           Urethral cancer in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/35/34357\">",
"           Urethral cancer in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/22/1380\">",
"           Urethral caruncle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/47/44792\">",
"           Urogenital tract fistulas in women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pediatric urology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/59/42937\">",
"           Acute cystitis in children older than two years and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/1/27674\">",
"           Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/40/21129\">",
"           Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/0/11271\">",
"           Clinical presentation and diagnosis of posterior urethral valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/3/39989\">",
"           Ectopic ureter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/47/26360\">",
"           Epidemiology and risk factors for urinary tract infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/60/6090\">",
"           Epidemiology of and risk factors for nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/21/40281\">",
"           Etiology and evaluation of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/50/25384\">",
"           Evaluation and diagnosis of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/42/22185\">",
"           Evaluation of inguinal swelling in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/59/24506\">",
"           Evaluation of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/27/7606\">",
"           Long-term management and prevention of urinary tract infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/0/7178\">",
"           Management of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/47/35577\">",
"           Management of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/44/712\">",
"           Neonatal testicular torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/60/22472\">",
"           Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21561\">",
"           Overview of inguinal hernia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/11/37048\">",
"           Pain syndromes in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/20/34119\">",
"           Postnatal management of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/23/15737\">",
"           Prenatal sonographic diagnosis of cystic renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/62/19432\">",
"           Prevention of recurrent nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/28/1479\">",
"           Primary megaureter in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/52/28487\">",
"           Renal ectopic and fusion anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/11/35000\">",
"           Scrotal trauma in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/36/11849\">",
"           Surgical management and postoperative outcome of children with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/3/10295\">",
"           The pediatric physical examination: The perineum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/44/17098\">",
"           Undescended testes (cryptorchidism) in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/44/4807\">",
"           Urinary tract infection in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/59/14264\">",
"           Urinary tract infections in newborns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Penile and scrotal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/16/3334\">",
"           Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/40/5770\">",
"           Anatomy and pathology of testicular tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/21/42328\">",
"           Carcinoma of the penis: Clinical presentation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/13/26840\">",
"           Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/47/41720\">",
"           Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/25/2457\">",
"           Epidemiology of and risk factors for testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/51/5942\">",
"           Evaluation of nonacute scrotal pathology in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44360\">",
"           Evaluation of the acute scrotum in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/18/18728\">",
"           Genital Chlamydia trachomatis infections in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/63/24568\">",
"           Initial risk-stratified treatment for advanced testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/38/19047\">",
"           Male dyspareunia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/29/26070\">",
"           Management of stage I nonseminomatous germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/44/712\">",
"           Neonatal testicular torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/7/13432\">",
"           Overview of the treatment of testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/45/9943\">",
"           Posttreatment follow-up for men with testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/63/33782\">",
"           Radical inguinal orchiectomy for testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/3/9272\">",
"           Retroperitoneal lymph node dissection in testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/17/24852\">",
"           Risk stratification of metastatic testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/58/38822\">",
"           Serum tumor markers in testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/1/42007\">",
"           Surgical management of Peyronie's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/33/38425\">",
"           Surgical management of advanced testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/27/42425\">",
"           Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/40/6789\">",
"           Testicular sex cord stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/56/2954\">",
"           Treatment of relapsed and refractory testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/2/22567\">",
"           Treatment of stage I seminoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/45/22230\">",
"           Treatment of stage II seminoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/49/20250\">",
"           Treatment-related toxicity in men with testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/42/44712\">",
"           Vasectomy and other vasal occlusion techniques for male contraception",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prostate disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/62/13288\">",
"           Active surveillance for men with early prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/41/41622\">",
"           Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/3/32824\">",
"           Brachytherapy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/7/16503\">",
"           Castrate resistant prostate cancer: Treatments targeting the androgen pathway",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/48/41736\">",
"           Chemoprevention strategies in prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/8/6280\">",
"           Chemotherapy in castrate-resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/19/17720\">",
"           Chronic prostatitis/chronic pelvic pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/53/36696\">",
"           Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/16/36101\">",
"           Clinical presentation and diagnosis of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/18/33061\">",
"           Clinical use of saw palmetto",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/63/43000\">",
"           Cryotherapy and other ablative techniques for the initial treatment of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/19/34104\">",
"           Epidemiology and pathogenesis of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/47/23290\">",
"           External beam radiation therapy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/52/10055\">",
"           Follow-up surveillance during and after treatment for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/41/8858\">",
"           Hyponatremia following transurethral resection or hysteroscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/14/1254\">",
"           Immunotherapy for castration resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/36/16969\">",
"           Initial approach to low-risk clinically localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/20/1353\">",
"           Initial hormone therapy for metastatic prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/26/21930\">",
"           Initial management of regionally localized intermediate and high risk prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/62/23527\">",
"           Initial staging and evaluation of men with newly diagnosed prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/52/24394\">",
"           Interpretation of prostate biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/59/20405\">",
"           Investigational approaches for the treatment of advanced prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/8/36999\">",
"           Management of bone metastases in advanced prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/2/41001\">",
"           Measurement of prostate specific antigen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/31/8698\">",
"           Medical treatment of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/9/30874\">",
"           Molecular biology of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/12/10442\">",
"           Overview of the treatment of disseminated prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/9/33943\">",
"           Pathologic stage T3 and margin positive prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/19/26937\">",
"           Precancerous lesions of the prostate: Pathology and clinical implications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/20/14666\">",
"           Prostate biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/55/24441\">",
"           Prostate cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/30/9704\">",
"           Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24313\">",
"           Radical prostatectomy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/39/1656\">",
"           Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/48/30470\">",
"           Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/48/33544\">",
"           Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/31/20983\">",
"           Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/0/38918\">",
"           Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/52/31562\">",
"           Risk factors for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/8/42122\">",
"           Screening for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/39/38520\">",
"           Secondary endocrine therapies for castration resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/30/21993\">",
"           Side effects of androgen deprivation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/7/40056\">",
"           Surgical and other invasive therapies of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reproductive and sexual function in men",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/54/11114\">",
"           Causes of male infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/52/30536\">",
"           Causes of primary hypogonadism in males",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/33/12824\">",
"           Clinical features and diagnosis of male hypogonadism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/24/13706\">",
"           Effects of cytotoxic agents on gonadal function in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/28/38341\">",
"           Erectile dysfunction in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/44/33481\">",
"           Evaluation of male infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/49/32533\">",
"           Evaluation of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/26/30120\">",
"           Hypogonadism in HIV-infected males",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/3/31800\">",
"           Male reproductive physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/47/35577\">",
"           Management of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/24/39306\">",
"           Overview of contraception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/44/42696\">",
"           Overview of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/13/4314\">",
"           Overview of testosterone deficiency in elderly men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/61/39893\">",
"           Overview of vasectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/29/20951\">",
"           Sexual dysfunction in uremic men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/17/16664\">",
"           Surgical treatment of erectile dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/57/42904\">",
"           The sexual history and approach to the patient with sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/33/3610\">",
"           Treatment of male infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/36/30282\">",
"           Treatment of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/42/44712\">",
"           Vasectomy and other vasal occlusion techniques for male contraception",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Upper urinary tract disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/41/38552\">",
"           Acute management of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/15/13561\">",
"           Acute uncomplicated cystitis and pyelonephritis in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/7/15479\">",
"           Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/32/28170\">",
"           Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/32/35336\">",
"           Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/50/20266\">",
"           Diagnosis and acute management of suspected nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/38/25190\">",
"           Diagnosis of urinary tract obstruction and hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/60/35785\">",
"           Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/9/2200\">",
"           Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/3/39989\">",
"           Ectopic ureter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/52/18250\">",
"           Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/22/29033\">",
"           Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/4/35910\">",
"           Hereditary kidney cancer syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/14/12522\">",
"           Immunotherapy of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/45/1754\">",
"           Malignancies of the renal pelvis and ureter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/18/40231\">",
"           Management of struvite or staghorn calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/28/27079\">",
"           Management of ureteral calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/21/37206\">",
"           Medullary sponge kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/62/30695\">",
"           Options in the management of renal and ureteral stones in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/40/4744\">",
"           Overview of renal disease associated with malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/1/21528\">",
"           Overview of the treatment of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/11/37048\">",
"           Pain syndromes in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/54/40802\">",
"           Pathogenesis and clinical manifestations of struvite stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/56/15242\">",
"           Placement and management of indwelling ureteral stents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/20/34119\">",
"           Postnatal management of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/23/15737\">",
"           Prenatal sonographic diagnosis of cystic renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/28/1479\">",
"           Primary megaureter in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/44/21192\">",
"           Prognostic factors in patients with renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/44/26310\">",
"           Radiofrequency ablation and cryoablation for renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/45/24276\">",
"           Recovery of renal function after relief of urinary tract obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/51/14134\">",
"           Renal and perinephric abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/52/28487\">",
"           Renal ectopic and fusion anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/11/30903\">",
"           Renal manifestations of autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/6/22630\">",
"           Role of surgery in patients with metastatic renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/3/27704\">",
"           Simple and complex renal cysts in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/26/5546\">",
"           Surgical management of localized renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/38/32360\">",
"           Surveillance for metastatic disease after nephrectomy for renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/58/39847\">",
"           The first kidney stone and asymptomatic nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/35/14904\">",
"           Treatment of retroperitoneal fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/62/3047\">",
"           Uric acid nephrolithiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/27/7609\">",
"           Urinary tract injury in gynecologic surgery: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/26/16804\">",
"           Xanthogranulomatous pyelonephritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic anatomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/27/41400\">",
"           Surgical female pelvic anatomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/41/16026\">",
"           Surgical female urogenital anatomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/48/36617\">",
"           Treatment of urethral stricture disease in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/59/15288\">",
"           Urinary tract complications of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/50/25384\">",
"           Evaluation and diagnosis of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/52/24394\">",
"           Interpretation of prostate biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/2/41001\">",
"           Measurement of prostate specific antigen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/1/42007\">",
"           Surgical management of Peyronie's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/40/43655\">",
"           Surgical repair of an iatrogenic ureteral injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/39/34418\">",
"           The significance of urinary eosinophils",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/42/4776\">",
"           Acute bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/47/10999\">",
"           Acute complicated cystitis and pyelonephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/59/42937\">",
"           Acute cystitis in children older than two years and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/1/27674\">",
"           Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/15/13561\">",
"           Acute uncomplicated cystitis and pyelonephritis in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/7/15479\">",
"           Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/19/42295\">",
"           Approach to the adult with asymptomatic bacteriuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/26/43433\">",
"           Approach to the adult with recurrent infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/36/12868\">",
"           Asymptomatic bacteriuria in patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/46/16102\">",
"           Bacterial adherence and other virulence factors for urinary tract infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/49/15128\">",
"           Candida infections of the bladder and kidneys",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/60/23496\">",
"           Chronic bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/19/17720\">",
"           Chronic prostatitis/chronic pelvic pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/40/21129\">",
"           Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/33/38426\">",
"           Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/57/35736\">",
"           Clinical manifestations and diagnosis of blastomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/30/34278\">",
"           Emphysematous urinary tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/47/26360\">",
"           Epidemiology and risk factors for urinary tract infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/18/18728\">",
"           Genital Chlamydia trachomatis infections in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/43/19126\">",
"           Infectious causes of dysuria in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/27/7606\">",
"           Long-term management and prevention of urinary tract infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/55/13178\">",
"           Overview of IgG4-related disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/11/29873\">",
"           Patient information: Prostatitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/51/14134\">",
"           Renal and perinephric abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/24/44422\">",
"           Urinary tract infection associated with urethral catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/44/4807\">",
"           Urinary tract infection in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/6/20579\">",
"           Urinary tract infection in renal transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/59/14264\">",
"           Urinary tract infections in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/41/24214\">",
"           Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/47/44792\">",
"           Urogenital tract fistulas in women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic malignancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/16/3334\">",
"           Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/62/13288\">",
"           Active surveillance for men with early prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/4/29766\">",
"           Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/40/5770\">",
"           Anatomy and pathology of testicular tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/32/28170\">",
"           Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/41/41622\">",
"           Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/3/32824\">",
"           Brachytherapy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/21/42328\">",
"           Carcinoma of the penis: Clinical presentation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/13/26840\">",
"           Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/7/16503\">",
"           Castrate resistant prostate cancer: Treatments targeting the androgen pathway",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/34/35367\">",
"           Chemoprevention of bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/48/41736\">",
"           Chemoprevention strategies in prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/8/6280\">",
"           Chemotherapy in castrate-resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/47/41720\">",
"           Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/32/35336\">",
"           Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/16/36101\">",
"           Clinical presentation and diagnosis of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/23/31096\">",
"           Complications of intravesical BCG immunotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/63/43000\">",
"           Cryotherapy and other ablative techniques for the initial treatment of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/61/26586\">",
"           Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/25/2457\">",
"           Epidemiology of and risk factors for testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/52/18250\">",
"           Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/47/29431\">",
"           Experimental systemic therapy of metastatic bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/47/23290\">",
"           External beam radiation therapy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/52/10058\">",
"           Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/52/10055\">",
"           Follow-up surveillance during and after treatment for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/4/35910\">",
"           Hereditary kidney cancer syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/14/1254\">",
"           Immunotherapy for castration resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/14/12522\">",
"           Immunotherapy of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/36/16969\">",
"           Initial approach to low-risk clinically localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/20/1353\">",
"           Initial hormone therapy for metastatic prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/26/21930\">",
"           Initial management of regionally localized intermediate and high risk prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/63/24568\">",
"           Initial risk-stratified treatment for advanced testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/62/23527\">",
"           Initial staging and evaluation of men with newly diagnosed prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/52/24394\">",
"           Interpretation of prostate biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/59/20405\">",
"           Investigational approaches for the treatment of advanced prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/39/5749\">",
"           Laparoscopic/robotic-assisted radical cystectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/45/1754\">",
"           Malignancies of the renal pelvis and ureter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/8/36999\">",
"           Management of bone metastases in advanced prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/29/26070\">",
"           Management of stage I nonseminomatous germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/9/30874\">",
"           Molecular biology of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/0/41992\">",
"           Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/29/40409\">",
"           Nonurothelial bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/40/4744\">",
"           Overview of renal disease associated with malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/44/2759\">",
"           Overview of the management of urothelial (transitional cell) bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/12/10442\">",
"           Overview of the treatment of disseminated prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/1/21528\">",
"           Overview of the treatment of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/7/13432\">",
"           Overview of the treatment of testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/9/33943\">",
"           Pathologic stage T3 and margin positive prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/53/27481\">",
"           Pathology of bladder neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/45/9943\">",
"           Posttreatment follow-up for men with testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/19/26937\">",
"           Precancerous lesions of the prostate: Pathology and clinical implications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/44/21192\">",
"           Prognostic factors in patients with renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/55/24441\">",
"           Prostate cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/30/9704\">",
"           Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/63/33782\">",
"           Radical inguinal orchiectomy for testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24313\">",
"           Radical prostatectomy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/44/26310\">",
"           Radiofrequency ablation and cryoablation for renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/3/9272\">",
"           Retroperitoneal lymph node dissection in testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/39/1656\">",
"           Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/48/30470\">",
"           Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/48/33544\">",
"           Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/0/38918\">",
"           Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/52/31562\">",
"           Risk factors for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/17/24852\">",
"           Risk stratification of metastatic testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/6/22630\">",
"           Role of surgery in patients with metastatic renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/8/42122\">",
"           Screening for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/39/38520\">",
"           Secondary endocrine therapies for castration resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/58/38822\">",
"           Serum tumor markers in testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/30/21993\">",
"           Side effects of androgen deprivation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/6/11366\">",
"           Small cell carcinoma of the bladder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/33/38425\">",
"           Surgical management of advanced testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/26/5546\">",
"           Surgical management of localized renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/38/32360\">",
"           Surveillance for metastatic disease after nephrectomy for renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/27/42425\">",
"           Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/40/6789\">",
"           Testicular sex cord stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/27/19897\">",
"           Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/11/40122\">",
"           Treatment of non-muscle-invasive bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/56/2954\">",
"           Treatment of relapsed and refractory testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/35/14904\">",
"           Treatment of retroperitoneal fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/2/22567\">",
"           Treatment of stage I seminoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/45/22230\">",
"           Treatment of stage II seminoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/49/20250\">",
"           Treatment-related toxicity in men with testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/26/10664\">",
"           Urethral cancer in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/35/34357\">",
"           Urethral cancer in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/63/1012\">",
"           Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/6/40041\">",
"           Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/49/12050\">",
"           Urine output in urinary tract obstruction and postobstructive diuresis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/9/33941\">",
"           Complications of urinary bladder catheters and preventive strategies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/39/5749\">",
"           Laparoscopic/robotic-assisted radical cystectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/56/15242\">",
"           Placement and management of indwelling ureteral stents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/47/40697\">",
"           Placement and management of urinary bladder catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/20/14666\">",
"           Prostate biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/7/40056\">",
"           Surgical and other invasive therapies of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/36/11849\">",
"           Surgical management and postoperative outcome of children with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/1/42007\">",
"           Surgical management of Peyronie's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/33/38425\">",
"           Surgical management of advanced testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/40/43655\">",
"           Surgical repair of an iatrogenic ureteral injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/17/16664\">",
"           Surgical treatment of erectile dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/48/36617\">",
"           Treatment of urethral stricture disease in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/42/44712\">",
"           Vasectomy and other vasal occlusion techniques for male contraception",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic stone disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/41/38552\">",
"           Acute management of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/19/13623\">",
"           Clinical features and diagnosis of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/19/1338\">",
"           Clinical manifestations of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/62/25577\">",
"           Cystine stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/45/38616\">",
"           Dent's disease (X-linked recessive nephrolithiasis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/50/20266\">",
"           Diagnosis and acute management of suspected nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/60/6090\">",
"           Epidemiology of and risk factors for nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/22/29033\">",
"           Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/2/35881\">",
"           Loin pain-hematuria syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/18/40231\">",
"           Management of struvite or staghorn calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/28/27079\">",
"           Management of ureteral calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/21/37206\">",
"           Medullary sponge kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/62/30695\">",
"           Options in the management of renal and ureteral stones in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/54/40802\">",
"           Pathogenesis and clinical manifestations of struvite stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/47/40697\">",
"           Placement and management of urinary bladder catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/62/19432\">",
"           Prevention of recurrent nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/45/24276\">",
"           Recovery of renal function after relief of urinary tract obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/58/39847\">",
"           The first kidney stone and asymptomatic nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/62/3047\">",
"           Uric acid nephrolithiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/49/12050\">",
"           Urine output in urinary tract obstruction and postobstructive diuresis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/26/16804\">",
"           Xanthogranulomatous pyelonephritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic symptoms and signs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/4/35912\">",
"           Acute urinary retention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/19/13623\">",
"           Clinical features and diagnosis of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/53/36696\">",
"           Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/19/1338\">",
"           Clinical manifestations of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/0/11271\">",
"           Clinical presentation and diagnosis of posterior urethral valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/14/29929\">",
"           Clinical presentation and diagnosis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/39/23161\">",
"           Cystitis in patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/45/38616\">",
"           Dent's disease (X-linked recessive nephrolithiasis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/38/25190\">",
"           Diagnosis of urinary tract obstruction and hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/60/35785\">",
"           Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/9/2200\">",
"           Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/30/16874\">",
"           Differential diagnosis of abdominal pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/59/34746\">",
"           Etiology and evaluation of hematuria in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/51/5942\">",
"           Evaluation of nonacute scrotal pathology in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44360\">",
"           Evaluation of the acute scrotum in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/10/22694\">",
"           Hematospermia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/2/35881\">",
"           Loin pain-hematuria syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/1/11290\">",
"           Lower urinary tract symptoms in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/38/19047\">",
"           Male dyspareunia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/22/43369\">",
"           Management of interstitial cystitis/bladder pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/0/7178\">",
"           Management of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/31/8698\">",
"           Medical treatment of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/11/37048\">",
"           Pain syndromes in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/8/8330\">",
"           Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/3/27704\">",
"           Simple and complex renal cysts in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/26/5546\">",
"           Surgical management of localized renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/17/16664\">",
"           Surgical treatment of erectile dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/39/34418\">",
"           The significance of urinary eosinophils",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/22/1380\">",
"           Urethral caruncle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/6/40041\">",
"           Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/11/35000\">",
"           Scrotal trauma in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/40/43655\">",
"           Surgical repair of an iatrogenic ureteral injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/27/7609\">",
"           Urinary tract injury in gynecologic surgery: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/46/14056\">",
"           Urinary tract injury in gynecologic surgery: Prevention",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-761FA54E0E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f31_54_32615=[""].join("\n");
var outline_f31_54_32615=null;
var title_f31_54_32616="Treatment of pheochromocytoma in adults";
var content_f31_54_32616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pheochromocytoma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Electron Kebebew, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32616/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/54/32616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytoma is a rare neuroendocrine tumor, occurring in less than 0.2 percent of patients with hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In at least 10 percent of patients, the tumor is discovered incidentally during CT or MRI of the abdomen for unrelated symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In one study, 19 of 33 patients (58 percent) with adrenal pheochromocytoma had their tumors discovered incidentally on imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/5\">",
"     5",
"    </a>",
"    ]. In other patients, the tumor is found only at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/6\">",
"     6",
"    </a>",
"    ]. Among patients suspected to have a pheochromocytoma, the diagnosis is rarely confirmed. In one series, as an example, the diagnosis was established in only 1 of 300 patients evaluated for pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of pheochromocytoma will be reviewed here (",
"    <a class=\"graphic graphic_algorithm graphicRef81154 \" href=\"mobipreview.htm?30/63/31728\">",
"     algorithm 1",
"    </a>",
"    ). The clinical manifestations, diagnosis, and genetics of pheochromocytoma, and management of metastatic pheochromocytoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link\">",
"     \"Pheochromocytoma in genetic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/38/14954?source=see_link\">",
"     \"Paraganglioma and pheochromocytoma: Management of malignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL PREPARATION FOR SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a pheochromocytoma is diagnosed, all patients should undergo a resection of the pheochromocytoma following appropriate medical preparation. Agents known to provoke a pheochromocytoma paroxysm (eg, glucagon, histamine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ) should be avoided.",
"   </p>",
"   <p>",
"    Resecting a pheochromocytoma is a high-risk surgical procedure and an experienced",
"    <span class=\"nowrap\">",
"     surgeon/anesthesiologist",
"    </span>",
"    team is required. Cardiovascular and hemodynamic variables must be monitored closely. Continuous measurement of intra-arterial pressure and heart rhythm is required. In the setting of congestive heart failure or decreased cardiac reserve, monitoring of pulmonary capillary wedge pressure is indicated.",
"   </p>",
"   <p>",
"    Preoperative medical therapy is aimed at:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Controlling hypertension (including preventing a hypertensive crisis during surgery)",
"     </li>",
"     <li>",
"      Volume expansion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with undiagnosed pheochromocytomas who undergo surgery for other reasons (and who therefore have not undergone preoperative medical therapy), surgical mortality rates are high due to lethal hypertensive crises, malignant arrhythmias, and multiorgan failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/8\">",
"     8",
"    </a>",
"    ]. Some form of preoperative pharmacologic preparation is indicated for all patients with catecholamine-secreting neoplasms. No randomized controlled trials have compared the different approaches and there is no universally accepted method of preparation for surgery in patients with pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/9\">",
"     9",
"    </a>",
"    ]. Combined alpha-adrenergic and beta-adrenergic blockade, calcium channel blockers, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/25/2452?source=see_link\">",
"     metyrosine",
"    </a>",
"    have all been used successfully and are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192460729\">",
"    <span class=\"h2\">",
"     Combined alpha- and beta-adrenergic blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined alpha- and beta-adrenergic blockade is one approach to control blood pressure and prevent intraoperative hypertensive crises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Alpha-adrenergic blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alpha-adrenergic blocker is given 10 to 14 days preoperatively to normalize blood pressure and expand the contracted blood volume. A longer duration of preoperative alpha-adrenergic blockade is indicated in patients with recent myocardial infarction, catecholamine cardiomyopathy, refractory hypertension, and catecholamine-induced vasculitis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38916?source=see_link\">",
"     Phenoxybenzamine",
"    </a>",
"    is the preferred drug for preoperative preparation to control blood pressure and arrhythmia in most centers in the United States. It is an irreversible, long-acting, nonspecific alpha-adrenergic blocking agent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial dose is 10 mg once or twice daily, and the dose is increased by 10 to 20 mg in divided doses every two to three days as needed to control blood pressure and spells.",
"     </li>",
"     <li>",
"      The final dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38916?source=see_link\">",
"       phenoxybenzamine",
"      </a>",
"      is typically between 20 and 100 mg daily. The patient should be warned about the orthostasis, nasal stuffiness, and marked fatigue that occur in almost all patients. Men should be counseled about retrograde ejaculation, as well.",
"     </li>",
"     <li>",
"      With their more favorable side-effect profiles, selective alpha1-adrenergic blocking agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36085?source=see_link\">",
"       terazosin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/59/8119?source=see_link\">",
"       doxazosin",
"      </a>",
"      ) are utilized in many centers or are preferred to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38916?source=see_link\">",
"       phenoxybenzamine",
"      </a>",
"      when long-term pharmacologic treatment is indicated (eg, for metastatic pheochromocytoma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192460828\">",
"    <span class=\"h4\">",
"     Blood pressure monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure should be monitored twice daily in the outpatient setting with the patient in the seated and standing positions. Target blood pressure is less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mm Hg (seated), with systolic blood pressure greater than 90 mm Hg (standing); both targets should be modified on the basis of the patient's age and comorbid disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192460836\">",
"    <span class=\"h4\">",
"     High sodium diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the second or third day of alpha-adrenergic blockade, patients are encouraged to start a diet high in sodium content (&gt;5000 mg daily) because of the catecholamine-induced volume contraction and the orthostasis associated with alpha-adrenergic blockade. This degree of volume expansion may be contraindicated in patients with congestive heart failure or renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Beta-adrenergic blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;After adequate alpha-adrenergic blockade has been achieved, beta-adrenergic blockade is initiated, which typically occurs two to three days preoperatively. The beta-adrenergic blocker should",
"    <strong>",
"     never",
"    </strong>",
"    be started first because blockade of vasodilatory peripheral beta-adrenergic receptors with unopposed alpha-adrenergic receptor stimulation can lead to a further elevation in blood pressure.",
"   </p>",
"   <p>",
"    The clinician should exercise caution if the patient is asthmatic or has congestive heart failure. Chronic catecholamine excess can produce a cardiomyopathy that may become evident with the initiation of beta-adrenergic blockade, resulting in acute pulmonary edema. Therefore, when the beta-adrenergic blocker is administered, it should be used cautiously and at a low dose:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, a patient is usually given 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      orally every six hours on the first day of beta-adrenergic blockade.",
"     </li>",
"     <li>",
"      On the second day, the beta-adrenergic blockade (assuming the patient tolerates the drug) is converted to a single long-acting dose.",
"     </li>",
"     <li>",
"      The dose is then increased as necessary to control the tachycardia (goal heart rate is 60 to 80 beats per minute).",
"     </li>",
"     <li>",
"      In general, the patient is ready for surgery in 10 to 14 days after initiation of alpha-adrenergic blockade.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although perioperative alpha-adrenergic blockade is widely recommended, a second regimen that has been utilized involves the administration of a calcium channel blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     Nicardipine",
"    </a>",
"    is the most commonly used calcium channel blocker in this setting; the starting dose is 30 mg twice daily of the sustained release preparation. It is given orally to control blood pressure preoperatively and is given as an intravenous infusion intraoperatively. Although there is less collective experience with calcium channel blockers than with alpha- and beta-adrenergic blockade, when calcium channel blockers are used as the primary mode of antihypertensive therapy, they may be as effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clearly, the exclusive use of calcium channel blockers for the perioperative management of patients with catecholamine-secreting tumors does not prevent all hemodynamic changes; however, its use has been associated with low morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main role for this class of drugs may be either to supplement the combined alpha- and beta-adrenergic blockade protocol when blood pressure control is inadequate or to replace the adrenergic blockade protocol in patients with intolerable side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Metyrosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach involves the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/25/2452?source=see_link\">",
"     metyrosine",
"    </a>",
"    (alpha-methyl-para-tyrosine), which inhibits catecholamine synthesis. In one report, the patients given metyrosine had a smoother perioperative course than those given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38916?source=see_link\">",
"     phenoxybenzamine",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/25/2452?source=see_link\">",
"     Metyrosine",
"    </a>",
"    should be used with caution and only when other agents have been ineffective or in patients where tumor manipulation or destruction (eg, radiofrequency ablation of metastatic sites) will be marked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/14\">",
"     14",
"    </a>",
"    ]. Although some centers advocate that this agent should be used routinely preoperatively, most reserve it primarily for patients who cannot be treated with the typical combined alpha- and beta-adrenergic blockade protocol because of intolerance or cardiopulmonary reasons.",
"   </p>",
"   <p>",
"    The protocol used at the Mayo Clinic with short-term preprocedure preparation is to start with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/25/2452?source=see_link\">",
"     metyrosine",
"    </a>",
"    250 mg every six hours on day one, 500 mg every six hours on day two, 750 mg every six hours on day three, and 1000 mg every six hours on the day before the procedure, with the last dose (1000 mg) the morning of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/15\">",
"     15",
"    </a>",
"    ]. With this short-course metyrosine therapy, the main side effect is hypersomnolence.",
"   </p>",
"   <p>",
"    The side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/25/2452?source=see_link\">",
"     metyrosine",
"    </a>",
"    can be disabling and with long-term therapy they include sedation, depression, diarrhea, anxiety, nightmares, crystalluria and urolithiasis, galactorrhea, and extrapyramidal signs. Metyrosine may be added to alpha- and beta-adrenergic blockade when the resection will be difficult (eg, malignant paraganglioma) or if destructive therapy is planned (eg, radiofrequency ablation of hepatic metastases or cryoablation of bone metastases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extrapyramidal effects of phenothiazines or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    may be potentiated and their use concomitantly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/25/2452?source=see_link\">",
"     metyrosine",
"    </a>",
"    should be avoided. High fluid intake to avoid crystalluria is suggested for any patient taking more than 2 g daily. The metyrosine-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38916?source=see_link\">",
"     phenoxybenzamine",
"    </a>",
"    regimen has not been compared with the phenoxybenzamine-beta-adrenergic blocker regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ADRENALECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscopic approach to the adrenal gland is the procedure of choice for patients with solitary intra-adrenal pheochromocytomas that are less than 8 cm in diameter and have no malignant radiologic features. Both the laparoscopic transabdominal and retroperitoneal approaches have been used successfully, although there is some evidence that the retroperitoneal approach is preferable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/16\">",
"     16",
"    </a>",
"    ]. A retrospective review reported better operative outcomes with the retroperitoneal approach as compared with the transabdominal approach with decreased operative time (84 versus 117 minutes), decreased intraoperative blood loss (200 mL versus 340 mL), shorter hospital stay (five versus eight days), and lower complication rates (7 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopic adrenalectomy can be safely performed for pheochromocytoma in more than 90 percent of cases. As an example, in an observational study of 102 patients with pheochromocytoma, 97 adrenalectomies were performed laparoscopically, seven were performed with open surgery, and four required conversion from laparoscopic to open surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the pheochromocytoma is in the adrenal gland, the entire gland should be removed in sporadic cases. Abdominal paragangliomas can also be approached laparoscopically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no curative treatments for malignant pheochromocytoma, unless the sites of disease are surgically resectable. We suggest resection with intent to cure, which may improve symptoms and possibly survival. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Malignant pheochromocytoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Partial adrenalectomy can be considered for familial pheochromocytoma. Familial pheochromocytoma is discussed below. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Familial pheochromocytoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Conversion to an open operation from laparoscopic surgery for pheochromocytoma or abdominal paragangliomas is indicated if the dissection is difficult or if malignant disease is found [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/38/14954?source=see_link\">",
"       \"Paraganglioma and pheochromocytoma: Management of malignant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Paragangliomas of the neck, chest, and urinary bladder require specialized approaches. For example, neck paragangliomas may be in the carotid sheath or in the carotid body and thus require proximal and distal vascular control for resection. Most chest paragangliomas require a median sternotomy and may involve the heart and great vessels with cardiac bypass, although videoscopic removal may be possible in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Familial pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 24 percent of pheochromocytomas and paragangliomas are associated with hereditary syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link&amp;anchor=H3#H3\">",
"     \"Pheochromocytoma in genetic disorders\", section on 'Familial pheochromocytoma'",
"    </a>",
"    .) Patients with familial pheochromocytomas (eg, multiple endocrine neoplasia type 2 [MEN2], von Hippel-Lindau [VHL]) have a high incidence of bilateral disease. Cortical-sparing bilateral adrenalectomy (partial adrenalectomy) may be considered for some patients with bilateral pheochromocytomas to prevent permanent glucocorticoid deficiency because some types of familial pheochromocytomas have less metastatic potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. In a retrospective series of 96 patients with hereditary pheochromocytomas, 39 underwent an intended cortical-sparing procedure as part of a bilateral adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/29\">",
"     29",
"    </a>",
"    ]. Acute adrenal insufficiency developed in only one patient, but two patients had a recurrence in their adrenal remnant requiring subsequent complete bilateral adrenalectomy.",
"   </p>",
"   <p>",
"    The management of patients with MEN2 and VHL differs as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with MEN2 have bilateral disease in 30 percent of cases and contralateral disease develops in 50 percent of the MEN2 patients with unilateral disease within 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/22,30,31\">",
"       22,30,31",
"      </a>",
"      ]. For these reasons, when bilateral adrenal pheochromocytomas are present, complete bilateral adrenalectomy is recommended for MEN2 patients. Patients with MEN2 have a high incidence of paroxysmal attacks and a higher prevalence of hypertension and other cardiovascular problems than do patients with VHL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with some forms of VHL have less diffuse medullary disease and cortical-sparing bilateral adrenalectomy is an option for these patients when bilateral disease is evident on imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/25\">",
"       25",
"      </a>",
"      ]. However, partial adrenalectomy potentially leaves residual adrenal medullary tissue behind, thus increasing the risk of recurrent pheochromocytoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/32\">",
"       32",
"      </a>",
"      ]. In one study, as an example, 13 of 14 patients with VHL did not require glucocorticoid therapy during a mean of 11 years of follow-up; however, three patients had recurrent pheochromocytoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/25\">",
"       25",
"      </a>",
"      ]. Similarly, in a study of 36 partial adrenalectomies in 26 patients with VHL, three patients became steroid dependent (11 percent) and there were five local recurrences (11 percent) with nine years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some variant forms of VHL (VHL type 2A) have high malignancy rates and cortical sparing adrenalectomy should be avoided in patients from these kindreds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/34\">",
"       34",
"      </a>",
"      ]. Patients with VHL should be referred for genetic counseling and screening for specific mutations associated with these variants. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=see_link\">",
"       \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a bilateral adrenalectomy is planned preoperatively, the patient should receive glucocorticoid stress coverage while awaiting transfer to the operating room. Glucocorticoid coverage should be initiated in the operating room if unexpected bilateral adrenalectomy is necessary. Complete bilateral adrenalectomy with autotransplantation of adrenocortical tissue has also been attempted, but has",
"    <strong>",
"     not",
"    </strong>",
"    been found to circumvent the need for life-long glucocorticoid replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgical outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no randomized trial data are available, observational studies and literature reviews report that intraoperative blood loss is less, operative time is shorter, length of hospital stay is shorter, and costs are lower with laparoscopic when compared with open adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/36-43\">",
"     36-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of surgery for pheochromocytoma are primarily due to severe preoperative hypertension, high secretion tumors, or repeat intervention for recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/44\">",
"     44",
"    </a>",
"    ]. As an example, in a series of 143 patients who had open surgery, adverse perioperative events or complications occurred in 32 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/45\">",
"     45",
"    </a>",
"    ]. The most common adverse event was sustained hypertension (36 patients). There were no perioperative deaths, myocardial infarctions, or cerebrovascular events. Preoperative factors associated with adverse perioperative events included larger tumor size, prolonged duration of anesthesia, and increased levels of preoperative urinary catecholamines and catecholamine metabolites. Despite premedication of most patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38916?source=see_link\">",
"     phenoxybenzamine",
"    </a>",
"    and a beta-adrenergic blocker, varying degrees of intraoperative hemodynamic lability occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complication rates are lower with laparoscopic surgery as compared with open surgery. In a report of 40,363 patients who underwent adrenalectomies between 1998 and 2006, the surgical outcomes were improved with laparoscopic adrenalectomy as compared with open surgery with regard to complication rates (4 versus 8 percent), pulmonary compromise (2 versus 4 percent), and length of hospital stay (three versus five days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute hypertensive crises",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of preoperative medical preparation, hemodynamic instability may still occur during surgical resection of a pheochromocytoma. Endotracheal intubation and manipulation of the adrenal gland can both induce release of catecholamines and, potentially, a hypertensive crisis.",
"   </p>",
"   <p>",
"    Potential risk factors for intraoperative hemodynamic instability were identified in a retrospective study of 73 patients undergoing surgical resection of a pheochromocytoma at a single institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/47\">",
"     47",
"    </a>",
"    ]. Higher preoperative plasma norepinephrine concentration, larger tumor size (&gt;4 cm), and more pronounced postural blood pressure fall after alpha-blockade (&gt;10 mm Hg) correlated with intraoperative hypertensive events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for hypertensive crises include intravenous sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      is an ideal vasodilator for intraoperative management of hypertensive episodes because of its rapid onset of action and short duration of effect. It is administered as an intravenous infusion at 0.5 to 5.0",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      of body weight per minute and adjusted every few minutes for target blood pressure response; to keep the steady-state thiocyanate concentration below 1",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      the rate of a prolonged infusion should be no more than 3",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/43/34485?source=see_link\">",
"       Phentolamine",
"      </a>",
"      is a short-acting, nonselective alpha-adrenergic blocker available in lyophilized form in 5 mg vials. An initial test dose of 1 mg is administered and, if necessary, followed by repeat 5 mg boluses or continuous infusion. The response to phentolamine is maximal in two to three minutes after a bolus injection and lasts 10 to 15 minutes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"       Nicardipine",
"      </a>",
"      can be started at an infusion rate of 5",
"      <span class=\"nowrap\">",
"       mg/hour",
"      </span>",
"      and titrated for blood pressure control (the infusion rate may be increased by 2.5",
"      <span class=\"nowrap\">",
"       mg/hour",
"      </span>",
"      every 15 minutes up to a maximum of 15",
"      <span class=\"nowrap\">",
"       mg/hour).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac arrhythmias should be managed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      (50 to 100 mg intravenously) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      (Brevibloc; 50 to 200 mcg per kg per minute intravenously).",
"     </li>",
"     <li>",
"      Postoperative hypotension can be avoided by adequate fluid replacement and hypoglycemia (which can occur in 10 to 15 percent of patients due to removal of catecholamine suppression of insulin secretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/48\">",
"       48",
"      </a>",
"      ]) by glucose infusion. After tumor removal, catecholamine secretion should fall to normal in approximately one week.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Malignant pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 10 percent of all catecholamine-secreting tumors are malignant; they are histologically and biochemically the same as benign ones. The risk of malignancy is higher for paragangliomas than for pheochromocytomas, especially if the patient has a mutation in succinate dehydrogenase subunit B, and is also higher in some forms of variant VHL. The only reliable clue to the presence of a malignant pheochromocytoma is local invasion or distant metastases, which may occur as long as 20 years after resection. The clinical features and management of malignant pheochromocytomas are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\", section on 'Tumor characteristics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/38/14954?source=see_link\">",
"     \"Paraganglioma and pheochromocytoma: Management of malignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of a pheochromocytoma does not always lead to long-term cure of pheochromocytoma or hypertension, even in patients with a benign tumor. In one series of 176 patients, pheochromocytoma recurred in 29 (16 percent) and the recurrence was malignant in 15 of the 29 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/49\">",
"     49",
"    </a>",
"    ]. Recurrence was more likely in patients with familial pheochromocytoma or familial paraganglioma, right adrenal tumors, and extraadrenal tumors.",
"   </p>",
"   <p>",
"    Thus, long-term monitoring is indicated in all patients, even those apparently cured. Most patients should have annual biochemical screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32616/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/27/1458?source=see_link\">",
"       \"Patient information: Pheochromocytoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytoma is a rare neuroendocrine tumor with serious and potentially lethal cardiovascular complications due to the effects of secreted catecholamines. Although the clinical presentation may be quite variable, the classic triad is considered to be episodic headache, sweating, and tachycardia in association with hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pre-operative preparation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with pheochromocytoma need to undergo preoperative alpha-adrenergic blockade; we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38916?source=see_link\">",
"       phenoxybenzamine",
"      </a>",
"      as the first line drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternative drug options and details for drug administration are outlined above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Alpha-adrenergic blockade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After adequate alpha-adrenergic blockade has been achieved, beta-adrenergic blockade is begun. For beta-adrenergic blockade, we suggest cautious, low dose administration. As an example, a patient is usually given 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      every six hours to start. On the second day of treatment, the beta-adrenergic blockade (assuming the patient tolerates the drug) is converted to a single long-acting dose. The dose is then increased as necessary to control the tachycardia (goal heart rate is 60 to 80 beats per minute). The beta-adrenergic blocker should",
"      <strong>",
"       never",
"      </strong>",
"      be started first.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the reduction in postoperative morbidity, hospital stay, and expense compared with open laparotomy, we suggest laparoscopic adrenalectomy by an experienced endocrine surgeon for adrenal pheochromocytomas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adrenalectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Familial pheochromocytoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with MEN2 (which is a diffuse medullary disease) with evidence of bilateral disease on imaging, we suggest complete bilateral adrenalectomy because of the risk of recurrent pheochromocytoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Familial pheochromocytoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with VHL (which is a less diffuse medullary disease) with evidence of bilateral disease on imaging, we suggest cortical-sparing bilateral adrenalectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Because of the risk of recurrent disease in these patients, we recommend long-term biochemical monitoring.",
"     </li>",
"     <li>",
"      For patients with a high malignancy rate in the kindred, we suggest not performing cortical-sparing adrenalectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with MEN2 or VHL with unilateral pheochromocytoma, we suggest unilateral adrenalectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients then need annual biochemical testing indefinitely for evidence of contralateral pheochromocytoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Malignant disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest resection of malignant pheochromocytoma with intent to cure, which may improve symptoms and possibly survival (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other treatment options for malignant pheochromocytoma are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/38/14954?source=see_link\">",
"       \"Paraganglioma and pheochromocytoma: Management of malignant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/1\">",
"      Young WF Jr. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord 2007; 8:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/2\">",
"      Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/3\">",
"      Kudva, YC, Young, WF Jr, Thompson, GB, et al. Adrenal incidentaloma: An important component of the clinical presentation spectrum of benign sporadic adrenal pheochromocytoma. The Endocrinologist 1999; 9:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/4\">",
"      Baguet JP, Hammer L, Mazzuco TL, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 2004; 150:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/5\">",
"      Motta-Ramirez GA, Remer EM, Herts BR, et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol 2005; 185:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/6\">",
"      Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int 1991; 40:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/7\">",
"      Fogarty J, Engel C, Russo J, et al. Hypertension and pheochromocytoma testing: The association with anxiety disorders. Arch Fam Med 1994; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/8\">",
"      Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg 2000; 179:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/9\">",
"      Tauzin-Fin P, Sesay M, Gosse P, Ballanger P. Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. Br J Anaesth 2004; 92:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/10\">",
"      Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC. Successful outcomes in pheochromocytoma surgery in the modern era. J Urol 1999; 161:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/11\">",
"      Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005; 60:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/12\">",
"      Combemale F, Carnaille B, Tavernier B, et al. [Exclusive use of calcium channel blockers and cardioselective beta-blockers in the pre- and per-operative management of pheochromocytomas. 70 cases]. Ann Chir 1998; 52:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/13\">",
"      Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosine and pheochromocytoma. Arch Intern Med 1997; 157:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/14\">",
"      McBride JF, Atwell TD, Charboneau WJ, et al. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol 2011; 22:1263.",
"     </a>",
"    </li>",
"    <li>",
"     Young WF Jr. Endocrine hypertension. In: Williams textbook of endocrinology, 12th Ed, Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (Eds), Saunders/Elsevier, Philadelphia 2011. p.545.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/16\">",
"      Nehs MA, Ruan DT. Minimally invasive adrenal surgery: an update. Curr Opin Endocrinol Diabetes Obes 2011; 18:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/17\">",
"      Li QY, Li F. Laparoscopic adrenalectomy in pheochromocytoma: retroperitoneal approach versus transperitoneal approach. J Endourol 2010; 24:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/18\">",
"      Shen WT, Grogan R, Vriens M, et al. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg 2010; 145:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/19\">",
"      Walz MK, Alesina PF, Wenger FA, et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg 2006; 30:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/20\">",
"      Shen WT, Sturgeon C, Clark OH, et al. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 2004; 136:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/21\">",
"      Brown ML, Zayas GE, Abel MD, et al. Mediastinal paragangliomas: the mayo clinic experience. Ann Thorac Surg 2008; 86:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/22\">",
"      Pacak K, Eisenhofer G, Ilias I. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens) 2009; 8:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/23\">",
"      Diner EK, Franks ME, Behari A, et al. Partial adrenalectomy: the National Cancer Institute experience. Urology 2005; 66:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/24\">",
"      Neumann HP, Reincke M, Bender BU, et al. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 1999; 84:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/25\">",
"      Baghai M, Thompson GB, Young WF Jr, et al. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 2002; 137:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/26\">",
"      Lee JE, Curley SA, Gagel RF, et al. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996; 120:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/27\">",
"      Walther MM, Herring J, Choyke PL, Linehan WM. Laparoscopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma. J Urol 2000; 164:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/28\">",
"      Yip L, Lee JE, Shapiro SE, et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 2004; 198:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/29\">",
"      Grubbs EG, Rich TA, Ng C, et al. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 2013; 216:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/30\">",
"      Kaltsas GA, Papadogias D, Grossman AB. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res 2004; 31:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/31\">",
"      Frank-Raue K, Kratt T, H&ouml;ppner W, et al. Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene. Eur J Endocrinol 1996; 135:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/32\">",
"      Brauckhoff M, Gimm O, Brauckhoff K, Dralle H. Repeat adrenocortical-sparing adrenalectomy for recurrent hereditary pheochromocytoma. Surg Today 2004; 34:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/33\">",
"      Benhammou JN, Boris RS, Pacak K, et al. Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol 2010; 184:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/34\">",
"      Nielsen SM, Rubinstein WS, Thull DL, et al. Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations. Am J Med Genet A 2011; 155A:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/35\">",
"      Okamoto T, Obara T, Ito Y, et al. Bilateral adrenalectomy with autotransplantation of adrenocortical tissue or unilateral adrenalectomy: treatment options for pheochromocytomas in multiple endocrine neoplasia type 2A. Endocr J 1996; 43:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/36\">",
"      Col V, de Canni&egrave;re L, Collard E, et al. Laparoscopic adrenalectomy for phaeochromocytoma: endocrinological and surgical aspects of a new therapeutic approach. Clin Endocrinol (Oxf) 1999; 50:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/37\">",
"      Gill IS, Soble JJ, Sung GT, et al. Needlescopic adrenalectomy--the initial series: comparison with conventional laparoscopic adrenalectomy. Urology 1998; 52:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/38\">",
"      Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004; 5:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/39\">",
"      Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg 2004; 91:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/40\">",
"      Cheah WK, Clark OH, Horn JK, et al. Laparoscopic adrenalectomy for pheochromocytoma. World J Surg 2002; 26:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/41\">",
"      Sprung J, O'Hara JF Jr, Gill IS, et al. Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma. Urology 2000; 55:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/42\">",
"      Ichikawa T, Mikami K, Suzuki H, et al. Laparoscopic adrenalectomy for pheochromocytoma. Biomed Pharmacother 2002; 56 Suppl 1:149s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/43\">",
"      Matsuda T, Murota T, Oguchi N, et al. Laparoscopic adrenalectomy for pheochromocytoma: a literature review. Biomed Pharmacother 2002; 56 Suppl 1:132s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/44\">",
"      Plouin PF, Duclos JM, Soppelsa F, et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001; 86:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/45\">",
"      Kinney MA, Warner ME, vanHeerden JA, et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg 2000; 91:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/46\">",
"      Murphy MM, Witkowski ER, Ng SC, et al. Trends in adrenalectomy: a recent national review. Surg Endosc 2010; 24:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/47\">",
"      Bruynzeel H, Feelders RA, Groenland TH, et al. Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma. J Clin Endocrinol Metab 2010; 95:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/48\">",
"      Akiba M, Kodama T, Ito Y, et al. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg 1990; 14:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32616/abstract/49\">",
"      Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90:2110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 142 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32616=[""].join("\n");
var outline_f31_54_32616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL PREPARATION FOR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192460729\">",
"      Combined alpha- and beta-adrenergic blockade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Alpha-adrenergic blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H192460828\">",
"      Blood pressure monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H192460836\">",
"      High sodium diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Beta-adrenergic blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Metyrosine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ADRENALECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Familial pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgical outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute hypertensive crises",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Malignant pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pre-operative preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Familial pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Malignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/142\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/142|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?30/63/31728\" title=\"algorithm 1\">",
"      Evaluate and treat pheo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/38/14954?source=related_link\">",
"      Paraganglioma and pheochromocytoma: Management of malignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/27/1458?source=related_link\">",
"      Patient information: Pheochromocytoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=related_link\">",
"      Pheochromocytoma in genetic disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_54_32617="Lichenoid drug eruption";
var content_f31_54_32617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80165%7EDERM%2F59258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80165%7EDERM%2F59258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous to violaceous papules with fine scale are present in this patient with a lichenoid drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lichenoid drug eruption manifesting as violaceous and hyperpigmented papules is present in this patient with dark skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32617=[""].join("\n");
var outline_f31_54_32617=null;
var title_f31_54_32618="Evaluation of infection in the older adult";
var content_f31_54_32618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of infection in the older adult",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32618/contributors\">",
"     Wendy Garlington, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32618/contributors\">",
"     Kevin High, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32618/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/54/32618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/54/32618/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/54/32618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1498255\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is the primary cause of death in one-third of individuals aged 65 years and older and is a contributor to death for many others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/1\">",
"     1",
"    </a>",
"    ]. Infection also has a marked impact on morbidity in older adults, exacerbating underlying illnesses and initiating functional decline.",
"   </p>",
"   <p>",
"    Multiple biologic, cultural, and societal factors account for the increased susceptibility of older adults to infection and their poorer outcomes when infected. These factors also alter the presentation of infectious syndromes in older adults and may necessitate treatment modifications.",
"   </p>",
"   <p>",
"    The aspects of infectious diseases unique to the older adult will be reviewed here. When available, recommendations for diagnostic evaluation and therapy for the older adult are provided. Multiple topics throughout UpToDate present detailed discussions of pathologic, diagnostic, and therapeutic aspects related to specific infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498008\">",
"    <span class=\"h1\">",
"     FACTORS CONTRIBUTING TO INCREASED RISK FOR INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundamental alterations in quantitative and qualitative immune response occur with aging, a process that has been called immune senescence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/52/15178?source=see_link\">",
"     \"Immune function in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immune function is further compromised by the increasing number of concomitant medical problems that occur with aging. Impaired immunity correlates more with an individual&rsquo;s disease burden than chronologic age. Older adults who have chronic diseases (eg, diabetes, chronic obstructive pulmonary disease, or heart failure) are more susceptible to common infections and exhibit poorer vaccine responses than those who do not have underlying health issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple age-related changes contribute to decreased protection from infection in older adults. These changes include: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alterations in the barriers posed by the skin, lungs, and gastrointestinal tract (and other mucosal linings), permitting invasion by pathogenic organisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes in cellular and humoral immunity including decreases in specific cell populations, loss of the proliferative capacity of immune cells, and decreased production of specific cytokines (eg, IL-2) that leads to increased risk for intracellular pathogens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. Impaired signal transduction after cytokine binding is also associated with impaired defense against fungal and viral pathogens.",
"     </li>",
"     <li>",
"      Decreased antibody response to vaccines, related to reductions in toll-like receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/5\">",
"       5",
"      </a>",
"      ] and senescence of CD8+ T cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/6\">",
"       6",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Reductions in immunoglobulin production and naive B-cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of infection is further exacerbated by communal residence or other social institutions for older persons in developed nations, such as daycare programs or senior centers. Institutionalization is a major risk factor not only for acquiring disease in general, but for acquiring disease due to antibiotic resistant organisms. Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), fluoroquinolone-resistant Streptococcus pneumoniae and multiply-resistant Gram-negative bacilli are more frequent causes of infection among institutionalized older patients than those who are community-dwelling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Antibiotic resistance is fostered in the nursing home setting by debilitated hosts, close proximity of residents, and persistent antibiotic pressure. A Canadian study found that 8 to 17 percent of nursing home residents were taking antibiotics at any given time, that 50 to 70 percent were exposed to antibiotics over the course of one year, and that 22 to 89 percent of this antibiotic use was inappropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498015\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES IN DIAGNOSIS AND MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498024\">",
"    <span class=\"h2\">",
"     Presentation of disease and prognostic indicators",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been known for centuries that older adults can have severe infection in the absence of typical signs or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Fever, the cardinal feature of infection, is absent in 30 to 50 percent of frail, older adults, even in the setting of serious infections like pneumonia or endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The blunted febrile response in older adults is due to changes in multiple systems responsible for thermoregulation: shivering, vasoconstriction, hypothalamic regulation, and thermogenesis by brown adipose tissue are all impaired with advanced age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Baseline body temperature is often lower than 37&ordm;C in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/18\">",
"     18",
"    </a>",
"    ]. Post-menopausal women have lower basal body temperatures than pre-menopausal women, and the presence of dementia, dependence in activities of daily living (ADLS), or a low body mass index (&lt;20",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    also increase the risk for lower body temperatures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/19\">",
"     19",
"    </a>",
"    ]. Since signs of infection are commonly atypical in the older adult population, a rise in temperature from baseline becomes an important indicator of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the frequent lack of fever, infections in older adults may be associated with a nonspecific decline in baseline functional status such as increased confusion, falling, and anorexia. For some seniors, exacerbations of underlying illness (eg, atrial fibrillation) may be the predominant feature of infection.",
"   </p>",
"   <p>",
"    Cognitive impairment further contributes to the atypical presentation of infections in older adults, reducing the capacity to communicate symptoms. Clinicians must be ready to pursue objective assessments such as laboratory and radiologic evaluations at a lower threshold in cognitively impaired patients, unless advanced directives and goals of care indicate otherwise.",
"   </p>",
"   <p>",
"    Given the often atypical and subtle ways in which infection presents in seniors, there has been substantial interest in biomarkers such as C-reactive protein and procalcitonin to help identify infection. Unfortunately, widely varying cutoffs for &ldquo;normal&rdquo; values has led to wide variation in sensitivity and specificity for these assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/21\">",
"     21",
"    </a>",
"    ]. In general, they add little to good clinical judgment for initial decision-making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100210296\">",
"    <span class=\"h3\">",
"     Fever definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively healthy, community-dwelling older adults may be appropriately managed using conventional definitions of fever. Fevers &gt;38&deg;C (100.4&ordm;F) indicate a potential for serious infection, while hypothermia relative to baseline body temperatures may signify severe infection or even sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Revision of parameters used to identify &lsquo;fever&rsquo; in frail older adults has been suggested, due to their altered febrile response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/19,20,22\">",
"     19,20,22",
"    </a>",
"    ]. Fever in frail older patients may be considered as one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single oral temperature &gt;37.8&deg;C (&gt;100&ordm;F)",
"     </li>",
"     <li>",
"      Persistent oral or tympanic membrane temperature &ge;37.2&deg;C (99.0&ordm;F)",
"     </li>",
"     <li>",
"      Rectal temperature &ge;37.5&deg;C (99.5&ordm;F)",
"     </li>",
"     <li>",
"      Rise in temperature of &ge;1.1&deg;C (&ge;2&deg;F) above baseline temperature",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498031\">",
"    <span class=\"h2\">",
"     Antibiotic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution, metabolism, and excretion of many drugs is altered with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/23\">",
"     23",
"    </a>",
"    ]. Of all the pharmacokinetic changes observed with advanced age, the most important is a decrease in glomerular filtration rate (GFR). In a report from the NHANES III study, 38 percent of individuals age 70 or older who did not have hypertension or diabetes had an estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 compared with 0.7 percent of individuals between the ages of 20 and 39 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=see_link\">",
"     \"Drug prescribing for older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20658511#H20658511\">",
"     \"Assessment of kidney function\", section on 'Change in GFR with aging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The simple rule &ldquo;start low, go slow&rdquo; is appropriate for dosing most medications in older patients. However, an important cautionary note must be sounded regarding certain antimicrobials (eg, fluoroquinolones) that have concentration-dependent activity. Higher doses of these antibiotics are more effective and less likely to engender resistance. Furthermore, revised 'cut-points' used to determine susceptibility to penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and other beta-lactam drugs are predicated on serum levels achieved by dosing at the higher end of the recommended range. Thus, it is important that older adults with serious infection receive a first antibiotic dose at the highest level with known safety profile, with subsequent dosing to maintain drug levels in the therapeutic range. This may take extra care with older adults in whom calculated creatinine clearance becomes less reliable with age.",
"   </p>",
"   <p>",
"    When possible, drug levels should be monitored to avoid toxicity or subtherapeutic dosing. This is particularly important for levels of antibiotics that have a narrow therapeutic index, such as aminoglycosides, with heightened concern in patients with a reduced GFR.",
"   </p>",
"   <p>",
"    Patient adherence to prescribed medications may be limited due to many factors that are more common in older adults, including poor cognitive function, impaired hearing or vision, polypharmacy, medication side effects, and economic issues (inability to afford medications).",
"   </p>",
"   <p>",
"    The choice of initial antibiotic is not different from that in younger patients for most routine infections. However, special consideration is indicated for older adults who reside in an institution where multi-drug resistant organisms are prevalent. Additionally, broader initial coverage may be appropriate in seriously ill older adults in whom sepsis, severe pneumonia, or other life-threatening infections are suspected, since outcomes (mortality, length of ICU stay) are improved when the initial antibiotic regimen is effective against the infecting organism or organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/25\">",
"     25",
"    </a>",
"    ]. Older individuals are more likely to have infections from more than one source (eg, genitourinary or gastrointestinal in addition to respiratory or skin). Thus coverage should be broad until the infecting organisms are identified. (See",
"    <a class=\"local\" href=\"#H1498045\">",
"     'Bacteremia and sepsis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Prompt institution of antibiotics may be particularly relevant to outcomes in seniors. In older adults with pneumonia, data suggest that delaying initiation of therapy for eight or more hours after admission to the hospital is associated with an increased risk of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/26\">",
"     26",
"    </a>",
"    ]. Since this study did not evaluate outcomes in younger patients, it is not known if the effect of delayed antibiotic initiation is more relevant in older compared to younger patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274615175\">",
"    <span class=\"h3\">",
"     Antibiotic drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic interactions occur with many medications commonly prescribed in older adults, particularly those drugs with a narrow therapeutic index. Significant interactions with commonly prescribed antibiotics are seen for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"     </li>",
"     <li>",
"      Oral hypoglycemic agents",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"     </li>",
"     <li>",
"      Antacids and H2 receptor antagonists",
"     </li>",
"     <li>",
"      Lipid lowering agents",
"     </li>",
"     <li>",
"      Lipophilic beta-blockers and non-dihydropyridine calcium channel blockers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The direction of the interaction may be hard to predict, and may even be biphasic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    increases concentrations of some drugs initially, but induction of hepatic enzymes may lead to reduced drug concentrations in a few days). Atrophic gastritis, a common entity in older adults, and use of H2-blockers or proton pump inhibitors can reduce the absorption of some antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ). Drug interactions, such as fluoroquinolones and antacids, may also reduce absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498038\">",
"    <span class=\"h1\">",
"     UNIQUE ASPECTS OF SPECIFIC INFECTIOUS SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following section will review major differences in the causative agents, evaluation, management and prevention of a variety of common infectious syndromes in older adults (",
"    <a class=\"graphic graphic_table graphicRef79173 \" href=\"mobipreview.htm?33/46/34542\">",
"     table 1",
"    </a>",
"    ). This review will not attempt to review all infections affecting older adults. Multiple topics in UpToDate address issues related to these and other infections, including tuberculosis, influenza, osteomyelitis, herpes zoster, and",
"    <span class=\"nowrap\">",
"     pacemaker/prosthetic",
"    </span>",
"    valve infections. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498045\">",
"    <span class=\"h2\">",
"     Bacteremia and sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared to young adults, older patients with bacteremia are less likely to have chills or sweating. Fever may be absent, but has been reported in 77 to 93 percent of bacteremic older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/21\">",
"     21",
"    </a>",
"    ]. Gastrointestinal and genitourinary sources of bacteremia are more common, and thus isolation of Gram-negative rods is more frequent in older adults, a trend that continues to increase throughout the eighth and ninth decades of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacteremia carries a poor prognosis with advanced age. For example, nosocomial Gram-negative bacteremia has a mortality rate of 5 to 35 percent in young adults and 37 to 50 percent in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/28\">",
"     28",
"    </a>",
"    ]. Factors contributing to increased mortality in older adults include the use of invasive devices such as intravenous or urinary catheters, presence of coexisting disease, reduced immune response mechanisms leading to more prolonged inflammation, and a greater incidence of end organ damage in the face of a septic episode (eg, acute respiratory distress syndrome or renal insufficiency).",
"   </p>",
"   <p>",
"    In a case control study of 830 hospitalized patients aged 65 years and older with a nosocomial bloodstream infection, risk factors for infection included male sex, obesity, recent surgery, urinary incontinence, and presence on admission of a low prognostic score, gastrotomy tube, or central line [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/29\">",
"     29",
"    </a>",
"    ]. In this study, 81 percent of infections were catheter-related, and methicillin resistant staphylococcus (MRSA) was the most common organism, accounting for 23 percent of the infections. The prevalence of MRSA, but not vancomycin-resistant enterococcus, increases with advancing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498052\">",
"    <span class=\"h2\">",
"     Fever of unknown origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever of unknown origin (FUO) is a classic medical syndrome defined as temperature &gt;38.3&deg;C (101&deg;F) for at least three weeks and undiagnosed after one week of medical evaluation. The differential diagnosis of FUO in older patients differs from that in younger adults (",
"    <a class=\"graphic graphic_table graphicRef59925 \" href=\"mobipreview.htm?29/21/30044\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15431?source=see_link\">",
"     \"Etiologies of fever of unknown origin in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Roughly a third of older patients with FUO have treatable infections (eg, intra-abdominal abscess, bacterial endocarditis, tuberculosis, perinephric abscess, or occult osteomyelitis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/32\">",
"       32",
"      </a>",
"      ]. Endocarditis and tuberculosis are more common in older adults than in younger patients.",
"     </li>",
"     <li>",
"      Giant cell arteritis (GCA, also known as temporal arteritis) and polymyalgia rheumatica (PMR) account for 19 percent of all FUO in the older population (",
"      <a class=\"graphic graphic_table graphicRef59925 \" href=\"mobipreview.htm?29/21/30044\">",
"       table 2",
"      </a>",
"      ). The evaluation of FUO in patients age &gt;60 years should include a rheumatological evaluation including early temporal artery biopsy, particularly if the erythrocyte sedimentation rate or liver enzymes are elevated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link\">",
"       \"Diagnosis of giant cell (temporal) arteritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although earlier references [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/30\">",
"       30",
"      </a>",
"      ] suggested malignancy, particularly lymphoma, was a more common cause of FUO in older adults, more recent series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/35,36\">",
"       35,36",
"      </a>",
"      ] suggest malignant disease as a cause of FUO occurs with similar frequency in old and young adults, perhaps due to the ability to establish a diagnosis by more aggressive",
"      <span class=\"nowrap\">",
"       imaging/CT",
"      </span>",
"      scanning before patients reach FUO definitions. In both young and older adults, non-Hodgkin&rsquo;s lymphoma accounts for the majority of cases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15431?source=see_link&amp;anchor=H12#H12\">",
"       \"Etiologies of fever of unknown origin in adults\", section on 'Malignancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare causes of FUO in older individuals include drug fever, deep venous thrombosis with or without pulmonary emboli, and hyperthyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498059\">",
"    <span class=\"h2\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis (IE) is often related to degenerative valvular disease, mitral valve prolapse, or a prosthetic valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/37\">",
"     37",
"    </a>",
"    ]. Older adults have a 4.6-fold higher risk for IE than the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/38\">",
"     38",
"    </a>",
"    ]. Streptococci and staphylococci are recovered from approximately 80 percent of older adults with IE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/37\">",
"     37",
"    </a>",
"    ] although enterococcal and Gram-negative organisms occur more commonly than in younger patients, likely explained by a greater incidence of gastrointestinal and genitourinary sources of bacteremia. Although there is some disagreement in different series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/33,37,38\">",
"     33,37,38",
"    </a>",
"    ], it appears that age alone does not influence mortality if one adequately controls for infecting organism and concurrent morbid conditions.",
"   </p>",
"   <p>",
"    The diagnosis of IE is often more difficult in older patients. Fever, leukocytosis, embolic events, splenomegaly, skin lesions (Osler nodes, Janeway lesions), and conjunctival hemorrhages are less common with advanced age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/39\">",
"     39",
"    </a>",
"    ]. Valvular vegetations are also less common, while intracardiac abscesses and paravalvular complications are relatively more common in older than younger adults; these localized infection sites may not be detected by transthoracic echocardiography (TTE). Thus, a lower threshold to perform transesophageal echocardiography (TEE) may be indicated in older patients. A negative echocardiogram, either transthoracic or transesophageal, however, will not exclude the diagnosis of IE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnostic approach to infective endocarditis\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older patients with IE should have therapy directed at the identified pathogen or the most likely causes if blood cultures are negative. For native valve endocarditis, older adults with penicillin-susceptible streptococcal IE should be treated with four weeks of a beta-lactam alone, rather than shorter courses that include combination therapy with an aminoglycoside, to reduce the risk of renal and ototoxicity. When an aminoglycoside is necessary throughout the course of therapy (eg, enterococcal IE), close attention to renal function-driven dosing and monitoring of serum trough levels is imperative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498066\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because HIV has primarily afflicted younger adults (in their twenties and thirties), most of the HIV literature defines &lsquo;older adults&rsquo; as those age 50 years or over. The success of highly-active antiretroviral therapy (HAART) has resulted in the long-term survival of many patients with HIV, increasing the number of older adults with this disorder.",
"   </p>",
"   <p>",
"    Additionally, newly-acquired infections are becoming more prevalent among older adults. Older Americans typically acquire HIV infection via sexual activity, and subjects &gt;50 years of age account for about 15 percent of all new diagnoses of AIDS in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/40\">",
"     40",
"    </a>",
"    ]. Many older individuals did not grow up in an era when sexually transmitted diseases (STDs), or methods of preventing STDs, were often discussed. Further, as concerns over pregnancy decline with age, use of barrier methods of contraception wane as well. Thus, this group is the least likely of all US adults to practice safe sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. A study of sexuality of older adults found that 39 to 67 percent of 65 to 74 year olds were sexually active, while activity in those &gt;75 ranged from 16.7 to 38.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lack of HIV awareness, affecting both patients and their clinicians, confounds appropriate diagnosis. Nonspecific symptoms such as poor appetite and weight loss and specific infections such as zoster, tuberculosis, or frequent pneumonias are often mistaken for symptoms related to aging or comorbidity and do not prompt HIV testing as they would in younger adults. Special consideration should be given to HIV as a potentially treatable cause of dementia in those with memory loss. However no literature has compared the relative likelihood of identifying and reversing dementia due to HIV infection, compared with other reversible causes of dementia (eg, thyroid disease, vitamin deficiency, or syphilis).",
"   </p>",
"   <p>",
"    HIV infection in older adults tends to present at more advanced stages than in younger individuals, likely due both to delayed diagnosis and impaired immune response. Untreated, HIV pursues a more rapidly progressive course in older adults (",
"    <a class=\"graphic graphic_figure graphicRef74307 \" href=\"mobipreview.htm?37/55/38782\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Additionally, HIV is impacted by comorbidities that are more common in older adults, including diabetes, cardiovascular disease, or renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Including measures of multi-morbidity has been shown to be a more accurate predictor of prognosis in HIV-infected patients versus only traditional HIV-related factors (eg, CD4 count, viral load) in the current era of effective anti-retroviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/49\">",
"     49",
"    </a>",
"    ]. Further, frailty, a syndrome of high vulnerability to disease and disability usually seen in much older adults, is more frequent at young ages in HIV-infected persons and predicts mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/50\">",
"     50",
"    </a>",
"    ]. Though early data suggested frailty and multimorbidity were associated with HIV wasting, more recent data suggest that, like the general population, obesity is the major risk factor for frailty and multimorbid disease in those with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Classic geriatric syndromes such as falls also appear to be prevalent at younger ages in those with HIV, and the risk is not predicted by HIV-specific variables, but by risk factors similar to those seen in older adults in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=see_link\">",
"     \"Frailty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11417?source=see_link\">",
"     \"Managing multiple comorbidities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for initiation of anti-HIV therapy are the same as in younger patients. Adherence to anti-HIV therapy is as good as or better in older adults than in young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, it is recommended that regardless of age, combination therapy for HIV be provided for older adults in accord with current general guidelines. The choice of anti-HIV medication should take into consideration the patient's comorbidities and possible drug-drug interactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=see_link\">",
"     \"HIV and the older patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498073\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults age 65 years and older account for &gt;50 percent of all pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Annual hospitalization rates in the United States for pneumonia are",
"    <span class=\"nowrap\">",
"     &lt;2/1000",
"    </span>",
"    in young adults, but",
"    <span class=\"nowrap\">",
"     12/1000",
"    </span>",
"    in community dwelling adults age &gt;75 years and",
"    <span class=\"nowrap\">",
"     32/1000",
"    </span>",
"    in elderly nursing home residents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An approach to the evaluation of an elderly patient with community acquired pneumonia (CAP) is to determine hemodynamic stability, oxygen needs, co-morbid illnesses and whether the patient can take oral medicines. Several prognostic formulas are available to assess severity and determine indications for hospitalization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link\">",
"     \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Pneumonia Severity Index (PSI), developed from the Pneumonia Patient Outcomes Research Team (PORT) cohort study, is widely applied (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/42/44705?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/58\">",
"       58",
"      </a>",
"      ]. The PSI is the only decision aid for risk stratification of patients with CAP that has had its effectiveness and safety for guiding the initial site of treatment demonstrated in randomized trials and other interventional studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link&amp;anchor=H3#H3\">",
"       \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\", section on 'Pneumonia Severity Index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another commonly used scoring system is CURB65 (confusion, uremia, respiratory rate, low blood pressure and age &gt;65). This easy scoring system has been validated in older adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link&amp;anchor=H10#H10\">",
"       \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\", section on 'CURB-65 score'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, different prognostic scoring systems can reach different conclusions. Prediction rules are intended to supplement rather than override the judgment of the physicians and factors not included in the predictors may be important in determining management for individual patients. These may include living conditions, underlying psychiatric issues, and overall condition of the patient when determining management.",
"   </p>",
"   <p>",
"    Comorbidity was the strongest independent predictor of mortality in older patients with community acquired pneumonia (CAP) (OR 4.1, 95% CI 21.-8.1) in one study, where comorbidity was defined as cancer, collagen vascular disease or advanced liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/60\">",
"     60",
"    </a>",
"    ]. Other independent risk factors include the presence of marked vital sign abnormalities on admission (temperature &lt;36.1&deg;F, blood pressure &lt;90 mmHg systolic, or pulse &gt;110 bpm) (OR 3.4, 2.1-5.4), serum creatinine &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    (OR 2.5, 1.5-4.2), debility (OR 2.3, 1.4-3.7), and age &gt;85 years (OR 1.8, 1.1-3.1). Mortality nearly doubles, comparing patients age 65 to 69 (7.8 percent) to those older than 90 years (15.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/54\">",
"     54",
"    </a>",
"    ]. However, the overall 30-day mortality rate for Medicare patients &gt;65 years with CAP has declined by 28 percent between 1999 and 2005, likely attributable to increased rates of vaccination against pneumococcus and influenza, and guideline-directed treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology of pneumonia in older adults differs from that of young adults. S. pneumoniae is still the predominant organism, but polymicrobial infection and gram-negative organisms (H. influenzae, L. pneumophila, M. catarrhalis, Klebsiella spp.) occur more commonly, particularly in patients with COPD or who reside in long-term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. S. aureus and respiratory viruses are also frequent causes of CAP in nursing home residents. Tuberculosis is more common in older adults since they are more likely to have been exposed to M. tuberculosis in the first half of the twentieth century. Recent trends in the microbiology of pneumonia in the elderly include identification of a newly discovered agent, human metapneumovirus, which should be suspected when significant wheezing or bronchospasm is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/64\">",
"     64",
"    </a>",
"    ]. Finally, C. pneumonia accounts for up to 10 percent of CAP in older adults and is most commonly a cause of CAP in adults age 65 to 79 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/65\">",
"     65",
"    </a>",
"    ]. A causative organism is not identified in approximately 60 percent of older adults with pneumonia. Older adults may have more difficulty producing good-quality expectorated sputum, and sputum induction may be underutilized as a tool to help in the determination of the microbiology of pulmonary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older adults are also more likely to have antibiotic-resistant bacteria as a cause of their disease. However, this is felt to be a consequence of comorbidity, site of residence (ie, nursing home) and prior antibiotic exposure, rather than of age alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/10,63\">",
"     10,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for CAP in older adults follows usual guidelines. However, the risk of MRSA and gram-negative organisms should be taken into account for patients who reside in nursing homes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274615775\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of pneumonia is a complex issue in older adults. Immunization for influenza and pneumococcus are the most important preventive strategies. While pneumococcal vaccination may not prevent pneumonia in older adults, rates of bacteremia and invasive pneumococcal disease are decreased in immunized patients, and mortality in older patients hospitalized with pneumonia is lower for patients who were vaccinated prior to admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older adults are at higher risk than young adults for aspiration pneumonia. A number of interventions (eg, positioning, dietary changes, drugs, oral hygiene, tube feeding) have been proposed to prevent aspiration, especially in elderly patients. However, a 2003 systematic review of randomized controlled trials of such measures found insufficient data to assess effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/68\">",
"     68",
"    </a>",
"    ]. In a trial comparing feeding thin liquids in the chin down position with two consistencies of thickened feedings (nectar-thickened or honey-thickened) in patients with dementia or Parkinson disease, aspiration as seen by videofluorography was decreased in the groups receiving thickened feedings but there was no difference in the incidence of aspiration pneumonitis at three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link&amp;anchor=H4#H4\">",
"     \"Aspiration pneumonia in adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Techniques for the prevention of aspiration in hospitalized patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=see_link&amp;anchor=H11#H11\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Preventing aspiration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498080\">",
"    <span class=\"h2\">",
"     Prosthetic device infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of implanted prosthetic devices (eg, prosthetic joints, cardiac pacemakers, artificial heart valves, vascular grafts) in individuals increases with advancing age. Goals of treatment, and the importance of maximizing functional status in older adults, may affect treatment choices for prosthetic joint infections. General treatment recommendations for prosthetic joint infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infected prosthetic devices are typically coated by microbial biofilms, complex structures that reduce antibiotic penetration and promote organisms resistant to typical antibiotic concentrations. Furthermore, many conditions associated with infected prostheses are accompanied by marked scarring and poor blood flow to the area. Thus, it is preferable to use bactericidal antibiotics in high doses, often combined with a second agent that penetrates biofilms and poorly perfused areas in high concentration and is active against organisms in the stationary phase (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    for staphylococci); addition of rifampin has been associated with improved outcomes in a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/71-73\">",
"     71-73",
"    </a>",
"    ], but the issues of drug-drug interactions mentioned above are important with use of rifampin.",
"   </p>",
"   <p>",
"    Two-stage procedures with device removal, prolonged antibiotic administration, and subsequent re-implantation of the device is usually considered the gold-standard of therapy.",
"   </p>",
"   <p>",
"    However, comorbidities and baseline impaired functional status may alter the risks and benefits of two-stage procedures. In many older adults, full explantation of the device may be relatively contraindicated by co-existing morbidity. In others, return to full functional status is not a realistic goal and thus additional surgeries to save function are not indicated.",
"   </p>",
"   <p>",
"    In those older adults in whom full functionality is the goal, the best chance for cure has been presumed to be a two-stage procedure with removal of the device. However, long periods of debility and being bed-bound are more likely to result in loss of functional status and perhaps independence in older adults and these outcomes are rarely considered in most trials that evaluate cure rates or survival as the primary endpoint of interest. Functional assessment should be the focus of subsequent clinical trials in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/74\">",
"     74",
"    </a>",
"    ]. A modeling study of prosthetic joint infection compared the options of two-stage",
"    <span class=\"nowrap\">",
"     explantation/reinsertion",
"    </span>",
"    with debridement of the prosthetic device and chronic suppression of infection with oral antibiotics in those age &ge;79 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/75\">",
"     75",
"    </a>",
"    ]. Assuming an annual relapse rate with debridement and oral antibiotics of 30 percent, quality-adjusted life-year gained and cost-effectiveness outcomes were better for the",
"    <span class=\"nowrap\">",
"     debridement/retention",
"    </span>",
"    strategy than a two-stage arthroplasty. These data should be confirmed in clinical trials, but the modeling study raises provocative questions about the best way to manage device infection in seniors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498087\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection (UTI) is the most common illness in adults age 65 and over [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/79\">",
"     79",
"    </a>",
"    ]. The incidence rate approaches 10 percent in women and 5.3 percent in men over the age of 80. Gram-negative bacilli (eg, E. coli, Enterobacter spp., Klebsiella spp., Proteus spp.) are most common, but there is an increase in more resistant isolates such as Pseudomonas aeruginosa, and gram-positive organisms including enterococci (E. fecalis and E. faecium), coagulase-negative staphylococci and Streptococcus agalactiae (group B strep), when compared to young adults.",
"   </p>",
"   <p>",
"    Asymptomatic bacteriuria occurs in up to 6 to 16 percent of women in the community and 25 to 54 percent of women in nursing homes, with a frequency in men about half those figures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/80\">",
"     80",
"    </a>",
"    ]. With the use of chronic catheters, rates are even higher (about 85 percent for condom catheters and nearly 100 percent for indwelling catheters). Numerous studies suggest that there is no clinical benefit when asymptomatic bacteriuria is treated, but treatment can lead to significant side effects, expense and potential for selection of resistant organisms. Thus, treatment is not recommended, even in the presence of white blood cells in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical guidelines from the Infectious Diseases Society of America for evaluation of infection in older residents of long-term care facilities advise that urinalysis and urine cultures should not be ordered for asymptomatic individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/22\">",
"     22",
"    </a>",
"    ]. Diagnostic testing should be reserved for residents with fever, dysuria, gross hematuria, worsening incontinence or suspected bacteremia.",
"   </p>",
"   <p>",
"    The clinical dilemma clinicians face is to determine what defines &ldquo;symptomatic&rdquo; in frail, often cognitively impaired seniors. Infections often present in subtle fashion in older adults. Diagnosis of a UTI in an elderly patient relies on clinical signs (eg, altered mental status) and symptoms, supported by laboratory data. Urine cultures in infected elderly patients may have lower colony counts (10",
"    <sup>",
"     2",
"    </sup>",
"    to 10",
"    <sup>",
"     3",
"    </sup>",
"    ) compared to 10",
"    <sup>",
"     5",
"    </sup>",
"    in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/82\">",
"     82",
"    </a>",
"    ]. Therapeutic antibiotic &lsquo;trials&rsquo; are not recommended, to avoid possible drug toxicity, drug-drug interaction and antimicrobial resistance. A reasonable paradigm to follow for initiation of treatment for presumptive urinary tract infection in nursing home patients has been developed by an expert panel (",
"    <a class=\"graphic graphic_table graphicRef61419 \" href=\"mobipreview.htm?41/11/42171\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When true urinary tract infection is documented in an older woman, therapy is based on the location of infection (upper versus lower tract disease) and likely causative agent. Lower tract UTIs (cystitis), characterized by dysuria, frequency, and urgency (NOT fever which indicates upper tract disease) are often treated with short courses of antibiotics (for three to five days) in young women. A systematic review comparing antibiotic course duration (single day, three to six days, or 7 to 14 days) for uncomplicated symptomatic lower UTI in elderly women found that three to six day courses were sufficient for treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper tract UTI (pyelonephritis) is typically characterized by fever, chills, nausea, and flank pain often accompanied by lower tract symptoms although, as with all infections, presentation in older adults may be more subtle. Upper tract infection requires longer courses of therapy than lower tract infection. Because of the excellent bioavailability of many antibiotics, particularly the fluoroquinolones, intravenous therapy is not essential if the patient can tolerate oral medications, is not septic, and the infecting organisms are sensitive to oral agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary tract infection in older men is frequently caused by concomitant prostate disease (primarily hyperplasia) or functional bladder impairment, such as poor bladder emptying due to diabetes with peripheral neuropathy. Thus, UTIs in men are considered complicated UTIs and short-course therapy in elderly men is inappropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=see_link\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498094\">",
"    <span class=\"h1\">",
"     INTERVENTIONS TO BOOST IMMUNITY AND/OR PREVENT INFECTION IN OLDER ADULTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358841234\">",
"    <span class=\"h2\">",
"     Nutritional supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Undernutrition is common in the elderly and has an adverse effect on the immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. Both protein-energy malnutrition and micronutrient deficits affect immunity, including deficiencies in zinc,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and vitamins C, E, B6 and B12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/88-91\">",
"     88-91",
"    </a>",
"    ]. Nutritional supplements have frequently been the focus of strategies to boost immune responses in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/92\">",
"     92",
"    </a>",
"    ], but randomized control trials with clinical endpoints are rare and often report conflicting findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. Thus, the state of the evidence does not allow specific recommendations for nutritional supplements at this time.",
"   </p>",
"   <p>",
"    The recommended dietary allowance (RDA) for protein in adults is",
"    <span class=\"nowrap\">",
"     0.8g/kg/day.",
"    </span>",
"    Older adults tend to eat less than younger individuals, particularly reducing protein intake that may contribute to a loss of muscle mass. In addition to replacing muscle, protein helps in wound healing, bone health and cardiovascular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. An observational study in older adults found an association between better health status over ten years and ingestion of between 0.8 to 1.2 g",
"    <span class=\"nowrap\">",
"     protein/kg/",
"    </span>",
"    compared to those with intake",
"    <span class=\"nowrap\">",
"     &lt;0.8g/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High protein intake in hospitalized patients resulted in improved nitrogen balance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/100\">",
"     100",
"    </a>",
"    ]. Improved muscle mass leads to a decreased risk of falls and protein supplementation after hip fracture can improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/101\">",
"     101",
"    </a>",
"    ]. While there is no consensus data regarding a recommended intake of protein, some authors have suggested 1.5 to",
"    <span class=\"nowrap\">",
"     2g/kg/day,",
"    </span>",
"    but increasing protein intake in the elderly is not without risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/102\">",
"     102",
"    </a>",
"    ]. A diet which consists of 1.2 g",
"    <span class=\"nowrap\">",
"     protein/kg/day",
"    </span>",
"    or higher in patients with renal disease is associated with declining kidney function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/103\">",
"     103",
"    </a>",
"    ]. There is controversy whether high protein diets lead to calcium retention or calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. High protein diets can increase bradykinesia in patients with Parkinson's disease and are not recommended for this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Overall, the patient&rsquo;s condition and comorbidities should be taken into account before advising a high protein diet either through eating protein directly or nutritional supplements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498102\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization schedules for adults in good health and those with medical conditions are shown in tables (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific vaccines are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498109\">",
"    <span class=\"h3\">",
"     Tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adults represent the group most \"at risk\" for tetanus. Antibody levels below those considered protective (&lt;0.01 units per ml) occur in 43 to 61 percent of men and 48 to 71 percent of women in the United States over the age of 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/108\">",
"     108",
"    </a>",
"    ]. If there is no documentation of an older adult having received a complete tetanus vaccine series, a series of three injections is indicated. A dose of Tdap may substitute for one of the Td doses in the 3-dose series. For adults who have completed an initial vaccine series, booster injections should be given at 10-year intervals. In the fall of 2010, the US Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged 65 years and older who anticipate having close contact with infants aged younger than one year (eg, grandparents, childcare providers, healthcare providers) and who have not previously received Tdap should receive a single dose of Tdap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. They also voted to recommend that a single dose of Tdap vaccine may be given in place of Td for adults aged 65 years and older who have not previously received Tdap. These recommendations are included in the ACIP&rsquo;s 2011 recommended adult immunization schedule (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498116\">",
"    <span class=\"h3\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal vaccine is indicated for all persons 65 years or older and many persons under age 65 with comorbid conditions. Repeat immunization is indicated at age 65 or thereafter for those who were immunized more than five years earlier and before age. Studies of revaccination reveal that adverse events are uncommon and mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/111\">",
"     111",
"    </a>",
"    ]. Thus, when the pneumococcal immunization history is unknown, the vaccine should be administered.",
"   </p>",
"   <p>",
"    The polysaccharide vaccine currently approved for use in older adults does not prevent mucosal disease such as sinusitis and has unclear efficacy for preventing pneumonia. However, there are strong data that suggest the vaccine reduces the risk of invasive disease (ie, bacteremia) and that it is cost effective for older, immune competent adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. Whether a protein-polysaccharide conjugate vaccine will further reduce risk is unclear. However, use of the pneumococcal conjugate vaccine in young children may secondarily reduce the risk to older adults through herd immunity and reduced exposure of older adults to pneumococci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/114\">",
"     114",
"    </a>",
"    ]. Since introduction of the conjugated-pneumococcal vaccine, given only to children, invasive pneumococcal disease due to the 7 vaccine serotypes declined in adults age &gt;65 years by 22 percent (",
"    <a class=\"graphic graphic_figure graphicRef68595 \" href=\"mobipreview.htm?1/56/1935\">",
"     figure 4",
"    </a>",
"    ). There has been concern that non-vaccine serotypes would increase under 'immunologic pressure.' Indeed, disease in older adults due to non-vaccine serotypes increased 5 percent over the same time, though this was not statistically significant. Vaccination with both the 13-valent pneumococcal conjugate vaccine and the 23-valent polysaccharide vaccine is recommended for immunocompromised adults, but not for average-risk adults (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"mobipreview.htm?11/48/12046\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/115\">",
"     115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498123\">",
"    <span class=\"h3\">",
"     Seasonal influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used influenza vaccine is a killed virus that is moderately immunogenic and requires annual injections due to antigenic drift and short-lived immunity (four to five months). While a live-attenuated virus vaccine is available, there are no data in subjects over the age of 60 and it is not recommended for use in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/116\">",
"     116",
"    </a>",
"    ]. A high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    is available for individuals &ge;65 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/117\">",
"     117",
"    </a>",
"    ]. FDA approval was based on data showing increased immunogenicity of the high-dose vaccine in older adults. However, the Advisory Committee on Immunization Practices has not stated a preference for this vaccine over the standard dose vaccine in older adults since there are no data demonstrating greater protection against influenza illness.",
"   </p>",
"   <p>",
"    Multiple evaluations of the injectable vaccine's efficacy reveal that, while protection is incomplete, the vaccine markedly reduces the severity of disease and subsequent rates of respiratory illness, hospitalization and mortality in elderly adults with estimated efficacy rates of 70 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/118\">",
"     118",
"    </a>",
"    ]. Medical personnel and caregivers for high-risk patients should also be immunized. Despite these recommendations, there is controversy as to whether the influenza vaccine is effective in those &ge;70 and whether bias in case-control studies leads to overestimation of effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/119\">",
"     119",
"    </a>",
"    ]. Nevertheless, until the controversy is settled, all experts agree there is very little risk and immunization should be given to all older adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In outbreak situations, chemoprophylaxis can protect older adults against influenza during the two weeks immediately after immunization until an antibody response provides protection, or for longer periods in persons who cannot receive the vaccine.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    are all effective for some strains of influenza A, but differ greatly by subtype (eg, H1N1, H3N2), and with regard to resistance patterns, cost, side effects, mechanism of action and mode of delivery. Only the neuraminidase inhibitors, zanamivir and oseltamivir, prevent influenza B. Zanamivir is administered via a 'disk-inhaler' system that is often difficult for older adults to use and thus, zanamivir is not the drug of choice for older adults in most situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/120\">",
"     120",
"    </a>",
"    ]. Treatment with antiviral therapy reduces the duration of illness by about 1 to 1.5 days if started within 24 hours of symptom onset and may lower the risk of hospitalization in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498130\">",
"    <span class=\"h3\">",
"     Zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;The varicella",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    (VZV) was first recommended for the prevention of shingles in adults aged 60 years or older in 2006. Prior to vaccination, data suggest that half of all persons that live to age 85 will develop zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/122\">",
"     122",
"    </a>",
"    ]. The zoster vaccine reduces the risk of developing zoster by 51.3 percent and the risk of post-herpetic neuralgia by 66 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/123\">",
"     123",
"    </a>",
"    ]. It is recommended that adults over the age of 60 receive one dose of zoster vaccine, regardless of whether they have had an episode of herpes zoster. There is no contraindication to vaccination for individuals with common chronic medical conditions, but the vaccine is contraindicated in persons who are immunocompromised and in those with an allergy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498137\">",
"    <span class=\"h3\">",
"     General recommendations to improve immunization rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, only 30 to 40 percent of eligible older adults receive pneumococcal vaccine, and 50 to 60 percent receive influenza vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/124\">",
"     124",
"    </a>",
"    ]. Many unvaccinated elderly adults diagnosed with invasive pneumococcal disease have had contact with the medical system within the prior 6 to 12 months. Thus vaccines remain underutilized despite opportunities for immunization. Importantly, influenza and pneumococcal vaccine can be administered simultaneously at different anatomic sites, as can influenza and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The CDC has recommended a multi-pronged strategy for improving vaccine administration rates in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/124\">",
"     124",
"    </a>",
"    ]. Strategies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age-based strategies: review immunizations in all persons at age 50, vaccinate those with appropriate indications (",
"      <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Organizational strategies (eg, standing orders): routine administration in elderly and at-risk patients in office, nursing home, hospital settings",
"     </li>",
"     <li>",
"      Community-based strategies: public health promotions focusing on undeserved, often inner-city populations and community outreach programs (senior centers, civic organizations, etc.)",
"     </li>",
"     <li>",
"      Provider-based strategies: Physician-reminder systems (chart checklists, computer-assisted flags, pre-hospital discharge, etc.) and, simultaneous",
"      <span class=\"nowrap\">",
"       pneumococcal/influenza",
"      </span>",
"      vaccines",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498144\">",
"    <span class=\"h1\">",
"     TRAVEL RECOMMENDATIONS FOR OLDER ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adults are among the most widely traveled members of society, and can present a clinical quandary for practitioners since comorbidities, drug interactions and adverse effects occur much more frequently in the elderly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Often recommended vaccines include typhoid, rabies, hepatitis A and B, Japanese encephalitis, meningococcal and yellow fever vaccines. A review of travel-related immunization recommendations in older adults suggests that although there may be reduced efficacy for some protein and polysaccharide vaccines, their administration is generally well tolerated. However, live-attenuated organism vaccines may be harmful in some older individuals, and should only be given when the risk is high and there is no alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/125\">",
"     125",
"    </a>",
"    ]. The best studied of these is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    . Death and hospitalization following yellow fever vaccination are 3.5 times more likely in those aged 65 to 74 years, and 9 times more likely in those &gt;75 years, compared to younger individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/54/32618/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemoprophylaxis for malaria can be challenging in older persons, particularly those with heart disease. Side effects are common for many agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    may produce dizziness, change in mental status, and bradycardia or prolonged QT intervals). There are many alternative regimens for malaria prophylaxis, but familiarity with current resistance patterns is essential and should guide one&rsquo;s choice for chemoprophylaxis. Clinicians are referred to the CDC web site",
"    <span class=\"nowrap\">",
"     (www.cdc.gov/travel)",
"    </span>",
"    for the latest recommendations based on geography and local resistance patterns. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diarrhea affects up to one-half of travelers to developing countries, and the elderly patient may be more prone to food-borne disease than young adults due to achlorhydria and slow motility. The primary treatment for traveler&rsquo;s diarrhea is replenishment of fluids and electrolytes which may be of particular relevance in seniors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotics, typically fluoroquinolones, are indicated when diarrhea is accompanied by fever, bloody stools, or does not promptly respond to fluid and electrolyte replacement (one to two days). Antimotility agents are generally considered safe when coadministered with antimicrobial therapy, but older adults prone to constipation should be cautious in the use of antimotility drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358841401\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older adults are at greater infection risk due to immune senescence, comorbidities, and communal residence. (See",
"      <a class=\"local\" href=\"#H1498008\">",
"       'Factors contributing to increased risk for infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical signs or symptoms of infection may be absent in older adults, even in the presence of severe infection. Older adults often have lower baseline body temperature, and febrile response to infection is blunted. Nonspecific decline in baseline function status (increased confusion, falling, anorexia) may signal infection. (See",
"      <a class=\"local\" href=\"#H1498024\">",
"       'Presentation of disease and prognostic indicators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic dosing should take into account reduced renal function with aging. However, it is important that older adults with serious infection receive a first antibiotic dose at the highest level with known safety profile. Institutionalized older adults are at increased risk for antibiotic resistance. (See",
"      <a class=\"local\" href=\"#H1498031\">",
"       'Antibiotic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal and genitourinary sources of bacteremia are more common in older adults, leading to increased prevalence of infections due to gram-negative bacteria. Mortality is increased with bacteremia in older adults; recombinant human activated protein C can decrease mortality due to severe sepsis in older adults but increases bleeding risk. (See",
"      <a class=\"local\" href=\"#H1498045\">",
"       'Bacteremia and sepsis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About one-third of older patients with fever of unknown origin have treatable infections (eg, intra-abdominal abscess, bacterial endocarditis, tuberculosis, perinephric abscess, or occult osteomyelitis). Giant cell arteritis should be considered in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H1498052\">",
"       'Fever of unknown origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older adults are at increased risk for infective endocarditis, with most infections due to streptococci or staphylococci. Valvular vegetations may be more difficult to detect with transthoracic echocardiogram than in younger individuals. Shortened antibiotic courses that combine a beta lactam and aminoglycoside are not advised due to increased risk for aminoglycoside toxicity in older patients. (See",
"      <a class=\"local\" href=\"#H1498059\">",
"       'Infective endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older adults are at increasing risk for HIV due to failure to use preventive measures. HIV infection in older adults presents at more advanced stages and is more rapidly progressive than in younger individuals. Combination therapy for HIV should be provided for older adults in accord with current guidelines. (See",
"      <a class=\"local\" href=\"#H1498066\">",
"       'HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumonia incidence is greatly increased in older adults. S. pneumoniae is the predominant organism, but polymicrobial and gram-negative infections occur more commonly. Tuberculosis is also more common, and MRSA should be considered for patients who reside in long-term care facilities. (See",
"      <a class=\"local\" href=\"#H1498073\">",
"       'Pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections related to prosthetic devices are more common in older patients. Although two-stage procedures, involving removal of the prosthetic device and antibiotic treatment, followed by reimplantation, are indicated for curative treatment for most younger patients, selected older patients may be best treated by debridement and ongoing antibiotic suppression to maximize functional benefit and avoid prolonged debility. (See",
"      <a class=\"local\" href=\"#H1498080\">",
"       'Prosthetic device infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic bacteriuria is common and should not lead to antibiotic treatment. Guidelines for initiating antibiotics in nursing home residents with possible urinary tract infection are presented (",
"      <a class=\"graphic graphic_table graphicRef61419 \" href=\"mobipreview.htm?41/11/42171\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1498087\">",
"       'Urinary tract infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunizations should be maintained for tetanus, pneumococcus, and influenza.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"       Zoster vaccine",
"      </a>",
"      should be administered once to immunocompetent individuals age 60 or older, including patients who have a history of herpes zoster infection. (See",
"      <a class=\"local\" href=\"#H1498102\">",
"       'Immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older adults are at significant risk for adverse effects to yellow fever vaccination, a live vaccine, which should be reserved for those with exceptionally high risk of exposure. Adverse effects to antimalarial agents are also more common in older adults. Antimotility drugs for management of diarrhea should be used cautiously in patients with a history of constipation. (See",
"      <a class=\"local\" href=\"#H1498144\">",
"       'Travel recommendations for older adults'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/1\">",
"      Mouton CP, Bazaldua OV, Pierce B, Espino DV. Common infections in older adults. Am Fam Physician 2001; 63:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/2\">",
"      Castle SC, Uyemura K, Fulop T, Makinodan T. Host resistance and immune responses in advanced age. Clin Geriatr Med 2007; 23:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/3\">",
"      Gomez CR, Boehmer ED, Kovacs EJ. The aging innate immune system. Curr Opin Immunol 2005; 17:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/4\">",
"      Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009; 22:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/5\">",
"      Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010; 184:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/6\">",
"      Goronzy JJ, Fulbright JW, Crowson CS, et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75:12182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/7\">",
"      List&igrave; F, Candore G, Modica MA, et al. A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann N Y Acad Sci 2006; 1089:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/8\">",
"      Pfister G, Weiskopf D, Lazuardi L, et al. Naive T cells in the elderly: are they still there? Ann N Y Acad Sci 2006; 1067:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/9\">",
"      Bradley SF. Issues in the management of resistant bacteria in long-term-care facilities. Infect Control Hosp Epidemiol 1999; 20:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/10\">",
"      Kupronis BA, Richards CL, Whitney CG, Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/11\">",
"      O'Fallon E, Schreiber R, Kandel R, D'Agata EM. Multidrug-resistant gram-negative bacteria at a long-term care facility: assessment of residents, healthcare workers, and inanimate surfaces. Infect Control Hosp Epidemiol 2009; 30:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/12\">",
"      Loeb M, Simor AE, Landry L, et al. Antibiotic use in Ontario facilities that provide chronic care. J Gen Intern Med 2001; 16:376.",
"     </a>",
"    </li>",
"    <li>",
"     Wunderlich CA. On the Temperature in Diseases: A Manual of Medical Thermometry, William Wood and Co, New York 1871. p.46.",
"    </li>",
"    <li>",
"     Osler W. The Principles and Practice of Medicine, D. Appleton, New York 1982. p.517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/15\">",
"      Henschke PJ. Infections in the elderly. Med J Aust 1993; 158:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/16\">",
"      Musgrave T, Verghese A. Clinical features of pneumonia in the elderly. Semin Respir Infect 1990; 5:269.",
"     </a>",
"    </li>",
"    <li>",
"     Bender BS, Scarpace PJ. Fever in the Elderly. In: Fever: Basic Mechanisms and Management, MacKowiak PA (Ed), Lippincott-Raven, Philadelphia 1997. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/18\">",
"      Gomolin IH, Aung MM, Wolf-Klein G, Auerbach C. Older is colder: temperature range and variation in older people. J Am Geriatr Soc 2005; 53:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/19\">",
"      Norman DC. Fever in the elderly. Clin Infect Dis 2000; 31:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/20\">",
"      Castle SC, Yeh M, Toledo SD, et al. Lowering the fever criterea improves detection of infections in nursing home residents. Aging Immunol Infect Dis 1993; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/21\">",
"      van Duin D. Diagnostic challenges and opportunities in older adults with infectious diseases. Clin Infect Dis 2012; 54:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/22\">",
"      High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/23\">",
"      Herring AR, Williamson JC. Principles of antimicrobial use in older adults. Clin Geriatr Med 2007; 23:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/24\">",
"      Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/25\">",
"      Kollef MH. The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am J Med 2003; 115:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/26\">",
"      Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/27\">",
"      Gavazzi G, Mallaret MR, Couturier P, et al. Bloodstream infection: differences between young-old, old, and old-old patients. J Am Geriatr Soc 2002; 50:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/28\">",
"      Pien BC, Sundaram P, Raoof N, et al. The clinical and prognostic importance of positive blood cultures in adults. Am J Med 2010; 123:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/29\">",
"      Kaye KS, Marchaim D, Chen TY, et al. Predictors of nosocomial bloodstream infections in older adults. J Am Geriatr Soc 2011; 59:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/30\">",
"      Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993; 41:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/31\">",
"      Esposito AL, Gleckman RA. Fever of unknown origin in the elderly. J Am Geriatr Soc 1978; 26:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/32\">",
"      Tal S, Guller V, Gurevich A, Levi S. Fever of unknown origin in the elderly. J Intern Med 2002; 252:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/33\">",
"      Mourad O, Palda V, Detsky AS. A comprehensive evidence-based approach to fever of unknown origin. Arch Intern Med 2003; 163:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/34\">",
"      Tal S, Guller V, Gurevich A. Fever of unknown origin in older adults. Clin Geriatr Med 2007; 23:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/35\">",
"      Ely EW, Angus DC, Williams MD, et al. Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 2003; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/36\">",
"      Barrier J, Schneebeli S, Peltier P. Les Fievres prolongees inexpliquees chez les personnes, agees. Concours Med 1982; 104:4679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/37\">",
"      Dhawan VK. Infective endocarditis in elderly patients. Clin Infect Dis 2002; 34:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/38\">",
"      Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002; 288:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/39\">",
"      Durante-Mangoni E, Bradley S, Selton-Suty C, et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 2008; 168:2095.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/hiv/topics/over50.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/41\">",
"      Stall R, Catania J. AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med 1994; 154:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/42\">",
"      Murphree DD, DeHaven MJ. Does grandma need condoms? Condom use among women in a family practice setting. Arch Fam Med 1995; 4:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/43\">",
"      Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/44\">",
"      Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged &gt; or =50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003; 36:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/45\">",
"      Wellons MF, Sanders L, Edwards LJ, et al. HIV infection: treatment outcomes in older and younger adults. J Am Geriatr Soc 2002; 50:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/46\">",
"      Shah SS, McGowan JP, Smith C, et al. Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis 2002; 35:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/47\">",
"      Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/48\">",
"      Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/49\">",
"      Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med 2010; 11:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/50\">",
"      Desquilbet L, Jacobson LP, Fried LP, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci 2011; 66:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/51\">",
"      Shah K, Hilton TN, Myers L, et al. A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus. J Am Geriatr Soc 2012; 60:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/52\">",
"      Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr 2012; 61:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/53\">",
"      Erlandson KM, Allshouse AA, Jankowski CM, et al. Risk factors for falls in HIV-infected persons. J Acquir Immune Defic Syndr 2012; 61:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/54\">",
"      Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/55\">",
"      Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/56\">",
"      Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005; 294:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/57\">",
"      Donowitz GR, Cox HL. Bacterial community-acquired pneumonia in older patients. Clin Geriatr Med 2007; 23:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/58\">",
"      Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/59\">",
"      Man SY, Lee N, Ip M, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007; 62:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/60\">",
"      Conte HA, Chen YT, Mehal W, et al. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am J Med 1999; 106:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/61\">",
"      Ruhnke GW, Coca-Perraillon M, Kitch BT, Cutler DM. Marked reduction in 30-day mortality among elderly patients with community-acquired pneumonia. Am J Med 2011; 124:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/62\">",
"      El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/63\">",
"      Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/64\">",
"      Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003; 187:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/65\">",
"      Ewig S, Torres A. Is Chlamydia pneumoniae an important pathogen in patients with community-acquired pneumonia? Eur Respir J 2003; 21:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/66\">",
"      Vila-C&oacute;rcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/67\">",
"      Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/68\">",
"      Loeb MB, Becker M, Eady A, Walker-Dilks C. Interventions to prevent aspiration pneumonia in older adults: a systematic review. J Am Geriatr Soc 2003; 51:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/69\">",
"      Logemann JA, Gensler G, Robbins J, et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. J Speech Lang Hear Res 2008; 51:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/70\">",
"      Robbins J, Gensler G, Hind J, et al. Comparison of 2 interventions for liquid aspiration on pneumonia incidence: a randomized trial. Ann Intern Med 2008; 148:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/71\">",
"      Berdal JE, Skr&aring;mm I, Mowinckel P, et al. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect 2005; 11:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/72\">",
"      Barber&aacute;n J, Aguilar L, Carroquino G, et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med 2006; 119:993.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/73\">",
"      Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011; 53:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/74\">",
"      High KP, Bradley S, Loeb M, et al. A new paradigm for clinical investigation of infectious syndromes in older adults: assessment of functional status as a risk factor and outcome measure. Clin Infect Dis 2005; 40:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/75\">",
"      Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis 2001; 32:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/76\">",
"      Betsch BY, Eggli S, Siebenrock KA, et al. Treatment of joint prosthesis infection in accordance with current recommendations improves outcome. Clin Infect Dis 2008; 46:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/77\">",
"      Toulson C, Walcott-Sapp S, Hur J, et al. Treatment of infected total hip arthroplasty with a 2-stage reimplantation protocol: update on \"our institution's\" experience from 1989 to 2003. J Arthroplasty 2009; 24:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/78\">",
"      Lieberman JR, Callaway GH, Salvati EA, et al. Treatment of the infected total hip arthroplasty with a two-stage reimplantation protocol. Clin Orthop Relat Res 1994; :205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/79\">",
"      Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/80\">",
"      Juthani-Mehta M. Asymptomatic bacteriuria and urinary tract infection in older adults. Clin Geriatr Med 2007; 23:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/81\">",
"      Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/82\">",
"      Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 2004; 38:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/83\">",
"      Loeb M, Bentley DW, Bradley S, et al. Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference. Infect Control Hosp Epidemiol 2001; 22:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/84\">",
"      Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev 2008; :CD001535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/85\">",
"      Lesourd BM, Mazari L. Immune responses during recovery from protein-energy malnutrition. Clin Nutr 1997; 16 Suppl 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/86\">",
"      Lesourd B. Protein undernutrition as the major cause of decreased immune function in the elderly: clinical and functional implications. Nutr Rev 1995; 53:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/87\">",
"      Lesourd BM. Nutrition and immunity in the elderly: modification of immune responses with nutritional treatments. Am J Clin Nutr 1997; 66:478S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/88\">",
"      Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation: effect on lymphocyte responses in elderly persons. Am J Clin Nutr 1987; 46:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/89\">",
"      Prasad AS, Fitzgerald JT, Hess JW, et al. Zinc deficiency in elderly patients. Nutrition 1993; 9:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/90\">",
"      Lesourd BM, Mazari L, Ferry M. The role of nutrition in immunity in the aged. Nutr Rev 1998; 56:S113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/91\">",
"      Barnett JB, Hamer DH, Meydani SN. Low zinc status: a new risk factor for pneumonia in the elderly? Nutr Rev 2010; 68:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/92\">",
"      High KP. Nutritional strategies to boost immunity and prevent infection in elderly individuals. Clin Infect Dis 2001; 33:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/93\">",
"      Forster SE, Powers HJ, Foulds GA, et al. Improvement in nutritional status reduces the clinical impact of infections in older adults. J Am Geriatr Soc 2012; 60:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/94\">",
"      Barringer TA, Kirk JK, Santaniello AC, et al. Effect of a multivitamin and mineral supplement on infection and quality of life. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/95\">",
"      Avenell A, Campbell MK, Cook JA, et al. Effect of multivitamin and multimineral supplements on morbidity from infections in older people (MAVIS trial): pragmatic, randomised, double blind, placebo controlled trial. BMJ 2005; 331:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/96\">",
"      Wilson MM, Purushothaman R, Morley JE. Effect of liquid dietary supplements on energy intake in the elderly. Am J Clin Nutr 2002; 75:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/97\">",
"      Stamler J, Elliott P, Kesteloot H, et al. Inverse relation of dietary protein markers with blood pressure. Findings for 10,020 men and women in the INTERSALT Study. INTERSALT Cooperative Research Group. INTERnational study of SALT and blood pressure. Circulation 1996; 94:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/98\">",
"      Hu FB, Stampfer MJ, Manson JE, et al. Dietary protein and risk of ischemic heart disease in women. Am J Clin Nutr 1999; 70:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/99\">",
"      Vellas BJ, Hunt WC, Romero LJ, et al. Changes in nutritional status and patterns of morbidity among free-living elderly persons: a 10-year longitudinal study. Nutrition 1997; 13:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/100\">",
"      Bos C, Benamouzig R, Bruhat A, et al. Nutritional status after short-term dietary supplementation in hospitalized malnourished geriatric patients. Clin Nutr 2001; 20:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/101\">",
"      Tkatch L, Rapin CH, Rizzoli R, et al. Benefits of oral protein supplementation in elderly patients with fracture of the proximal femur. J Am Coll Nutr 1992; 11:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/102\">",
"      Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr 2008; 27:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/103\">",
"      Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/104\">",
"      Roughead ZK. Is the interaction between dietary protein and calcium destructive or constructive for bone? J Nutr 2003; 133:866S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/105\">",
"      Heaney RP. Protein intake and the calcium economy. J Am Diet Assoc 1993; 93:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/106\">",
"      Tsui JK, Ross S, Poulin K, et al. The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology 1989; 39:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/107\">",
"      Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 1987; 44:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/108\">",
"      Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995; 332:761.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccines/recs/acip/slides-oct10.htm (Accessed on November 10, 2010).",
"    </li>",
"    <li>",
"     Vaccine panel expands whooping cough coverage.",
" file://www.reuters.com/article/idUSTRE69Q5UL20101027 (Accessed on November 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/111\">",
"      Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/112\">",
"      Cornu C, Yz&egrave;be D, L&eacute;ophonte P, et al. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19:4780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/113\">",
"      Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/114\">",
"      Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/115\">",
"      Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/116\">",
"      Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/117\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged &gt;or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/118\">",
"      Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; :CD004876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/119\">",
"      Nelson JC, Jackson ML, Weiss NS, Jackson LA. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. J Clin Epidemiol 2009; 62:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/120\">",
"      Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001; 322:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/121\">",
"      Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/122\">",
"      Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/123\">",
"      Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/124\">",
"      Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/125\">",
"      Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 2001; 33:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/54/32618/abstract/126\">",
"      Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7:945.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14606 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32618=[""].join("\n");
var outline_f31_54_32618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H358841401\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1498255\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1498008\">",
"      FACTORS CONTRIBUTING TO INCREASED RISK FOR INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1498015\">",
"      GENERAL ISSUES IN DIAGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498024\">",
"      Presentation of disease and prognostic indicators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100210296\">",
"      - Fever definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498031\">",
"      Antibiotic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274615175\">",
"      - Antibiotic drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1498038\">",
"      UNIQUE ASPECTS OF SPECIFIC INFECTIOUS SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498045\">",
"      Bacteremia and sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498052\">",
"      Fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498059\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498066\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498073\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274615775\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498080\">",
"      Prosthetic device infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498087\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1498094\">",
"      INTERVENTIONS TO BOOST IMMUNITY AND/OR PREVENT INFECTION IN OLDER ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H358841234\">",
"      Nutritional supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498102\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1498109\">",
"      - Tetanus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1498116\">",
"      - Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1498123\">",
"      - Seasonal influenza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1498130\">",
"      - Zoster",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1498137\">",
"      - General recommendations to improve immunization rates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1498144\">",
"      TRAVEL RECOMMENDATIONS FOR OLDER ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H358841401\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14606\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14606|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/55/38782\" title=\"figure 1\">",
"      Persons surviving after AIDS diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/52/37701\" title=\"figure 2\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/17/42263\" title=\"figure 3\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/56/1935\" title=\"figure 4\">",
"      Reduction in invasive pneumococcal disease in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14606|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/46/34542\" title=\"table 1\">",
"      Predisposing factors and clinical aspects of infectious syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/21/30044\" title=\"table 2\">",
"      Causes of FUO in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/11/42171\" title=\"table 3\">",
"      Criteria for initiation of antibiotics for UTI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/48/12046\" title=\"table 4\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/42/44705?source=related_link\" title=\"calculator 1\">",
"      Calculator: Community-acquired pneumonia severity index (PSI) for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=related_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=related_link\">",
"      Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15431?source=related_link\">",
"      Etiologies of fever of unknown origin in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=related_link\">",
"      HIV and the older patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/52/15178?source=related_link\">",
"      Immune function in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11417?source=related_link\">",
"      Managing multiple comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_54_32619="Antifibrotic Rx for scleroderma";
var content_f31_54_32619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antifibrotic therapies for systemic sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D-penicillamine",
"       </td>",
"       <td>",
"        Inhibits the formation of stable collagen cross-links by forming hydroxy-lysine aldehyde and lysine groups on collagen precursors.",
"       </td>",
"       <td>",
"        Widely used in UK, doses above 750 mg daily probably needed for any benefit. Open studies have shown beneficial effects on lung, skin and kidney disease in SSc. Placebo controlled trial currently underway in USA.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon alpha",
"       </td>",
"       <td>",
"        Inhibits collagen production by dermal SSc fibroblasts in vitro, at transcriptional level. May also eliminate high collagen producing fibroblast subpopulations.",
"       </td>",
"       <td>",
"        Efficacy has been confirmed in open studies and a placebo controlled trial is currently underway in UK. Benefits must be balanced by the considerable morbidity of IFN administration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon gamma",
"       </td>",
"       <td>",
"        Similar to interferon alpha.",
"       </td>",
"       <td>",
"        Initial support for use from open studies and in vitro properties, but subsequent evaluation has been less favorable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colchicine",
"       </td>",
"       <td>",
"        Inhibition of collagen production by disrupting microtubule formation in fibroblast cytoskeleton. Possible enhancement of collagenase activity.",
"       </td>",
"       <td>",
"        Little used in most centers.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32619=[""].join("\n");
var outline_f31_54_32619=null;
var title_f31_54_32620="DDx FL path";
var content_f31_54_32620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of follicular lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Entity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immunophenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic features/other",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Follicular lymphoma",
"       </td>",
"       <td>",
"        Nodular growth pattern of follicle center cells (centrocytes and centroblasts). Tingible body macrophages usually absent.",
"       </td>",
"       <td>",
"        <p>",
"         Typically express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA. Ki-67 low.",
"        </p>",
"        Cytoplasmic staining for BCL-2 protein is strongly positive in almost all grade I/II&nbsp;follicular lymphoma&nbsp;tumors",
"       </td>",
"       <td>",
"        No single chromosomal change is diagnostic. t(14;18) present in 85 percent. Abnormalities in 3q27 present in 5 to 15 percent.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Reactive follicular hyperplasia",
"       </td>",
"       <td>",
"        Discrete follicles of varying sizes and shapes are separated from one another by interfollicular regions rich in T cells within the lymph node cortex. Prominent tingible body macrophages.",
"       </td>",
"       <td>",
"        <p>",
"         Typically express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA. Ki-67 high.",
"        </p>",
"        BCL-2 negative",
"       </td>",
"       <td>",
"        No specific genetic features",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Mantle cell lymphoma",
"       </td>",
"       <td>",
"        Monomorphous small to medium-sized B lymphocytes with irregular nuclei. No proliferation centers.",
"       </td>",
"       <td>",
"        <p>",
"         CD5+ and CD10-",
"        </p>",
"        The vast majority overexpress cyclin D1",
"       </td>",
"       <td>",
"        t(11;14)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Diffuse large B cell lymphoma: T cell rich large B cell lymphoma subtype",
"       </td>",
"       <td>",
"        Infiltrating small cells (reactive T cells) are present with interspersed larger cells that resemble centroblasts",
"       </td>",
"       <td>",
"        Larger neoplastic cells express pan B-cell antigens (CD19, CD20, CD79a), and monoclonal surface membrane IgM. Smaller cells are reactive and express T cell antigens.",
"       </td>",
"       <td>",
"        Genetic abnormalities varied",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Marginal zone lymphoma",
"       </td>",
"       <td>",
"        May have a partially nodular pattern of growth",
"       </td>",
"       <td>",
"        &gt;95 percent CD10-",
"       </td>",
"       <td>",
"        Lacks t(11;14) and t(14;18)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histologic transformation to diffuse large B cell lymphoma",
"       </td>",
"       <td>",
"        Large, transformed B cells with prominent nucleoli and basophilic cytoplasm demonstrating a diffuse growth pattern and a high (&gt;40 percent) proliferation fraction",
"       </td>",
"       <td>",
"        Express pan B cell antigens (CD19, CD20, CD79a), CD45, and monoclonal surface membrane IgM. Some cases will demonstrate CD5.",
"       </td>",
"       <td>",
"        Often t(14;18) positive; various other genetic aberrations",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32620=[""].join("\n");
var outline_f31_54_32620=null;
var title_f31_54_32621="Epirub cum dose cardiotox";
var content_f31_54_32621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The cumulative dose of epirubicin (in mg/m",
"    <sup>",
"     2",
"    </sup>",
"    ) corresponding to a 5 percent risk of developing heart failure during a follow-up time of 2.5 years after the initiation of epirubicin treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"15%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Patient characteristics",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Age at epirubicin start, years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        40",
"       </td>",
"       <td class=\"subtitle2\">",
"        50",
"       </td>",
"       <td class=\"subtitle2\">",
"        60",
"       </td>",
"       <td class=\"subtitle2\">",
"        70",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        <em>",
"         The recommended maximum epirubicin doses are given for patients with performance status less than 2, one or more metastatic sites, and no previous adjuvant chemotherapy. Shown are the recommended maximum cumulative doses for patients with one metastasis/more than one metatasis.",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Patients treated with first-line epirubicin as the only risk factor for HF:",
"       </td>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        806/844",
"       </td>",
"       <td rowspan=\"2\">",
"        739/782",
"       </td>",
"       <td rowspan=\"2\">",
"        673/722",
"       </td>",
"       <td rowspan=\"2\">",
"        609/665",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Previous antihormonal therapy*: no",
"        </p>",
"        <p>",
"         Previous CMF treatment: no",
"        </p>",
"        <p>",
"         Previous mediastinal irradiation: no",
"        </p>",
"        <p>",
"         Predisposition to heart disease",
"         <sup>",
"          &bull;",
"         </sup>",
"         : no",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Patients also treated previously with antihormonal drugs* for metastatic disease:",
"       </td>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        626/670",
"       </td>",
"       <td rowspan=\"2\">",
"        561/610",
"       </td>",
"       <td rowspan=\"2\">",
"        496/552",
"       </td>",
"       <td rowspan=\"2\">",
"        434/496",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Previous antihormonal therapy: yes",
"        </p>",
"        <p>",
"         Previous CMF treatment: no",
"        </p>",
"        <p>",
"         Previous mediastinal irradiation: no",
"        </p>",
"        <p>",
"         Predisposition to heart disease: no",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Patients also treated previously with CMF for metastatic disease:",
"       </td>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        864/883",
"       </td>",
"       <td rowspan=\"2\">",
"        828/850",
"       </td>",
"       <td rowspan=\"2\">",
"        793/818",
"       </td>",
"       <td rowspan=\"2\">",
"        759/786",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Previous antihormonal therapy: no",
"        </p>",
"        <p>",
"         Previous CMF treatment: yes",
"        </p>",
"        <p>",
"         Previous mediastinal irradiation: no",
"        </p>",
"        <p>",
"         Predisposition to heart disease: no",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Patients also treated previously with antihormonal drugs and CMF:",
"       </td>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        769/790",
"       </td>",
"       <td rowspan=\"2\">",
"        734/757",
"       </td>",
"       <td rowspan=\"2\">",
"        699/725",
"       </td>",
"       <td rowspan=\"2\">",
"        665/694",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Previous antihormonal therapy: yes",
"        </p>",
"        <p>",
"         Previous CMF treatment: yes",
"        </p>",
"        <p>",
"         Previous mediastinal irradiation: no",
"        </p>",
"        <p>",
"         Predisposition to heart disease: no",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Patients also treated previously with mediastinal irradiation",
"        <sup>",
"         &Delta;",
"        </sup>",
"        :",
"       </td>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        NA/640",
"       </td>",
"       <td rowspan=\"2\">",
"        NA/581",
"       </td>",
"       <td rowspan=\"2\">",
"        NA/523",
"       </td>",
"       <td rowspan=\"2\">",
"        NA/467",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Previous antihormonal therapy: no",
"        </p>",
"        <p>",
"         Previous CMF treatment: no",
"        </p>",
"        <p>",
"         Previous mediastinal irradiation: yes",
"        </p>",
"        <p>",
"         Predisposition to heart disease: no",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        Patients also with predisposition to heart disease",
"        <sup>",
"         &bull;",
"        </sup>",
"        :",
"       </td>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        491/539",
"       </td>",
"       <td rowspan=\"2\">",
"        427/481",
"       </td>",
"       <td rowspan=\"2\">",
"        364/424",
"       </td>",
"       <td rowspan=\"2\">",
"        303/369",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Previous antihormonal therapy: no",
"        </p>",
"        <p>",
"         Previous CMF treatment: no",
"        </p>",
"        <p>",
"         Previous mediastinal irradiation: no",
"        </p>",
"        <p>",
"         Predisposition to heart disease: yes",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HF: heart failure; CMF: cyclophosphamide, methotrexate, 5-fluorouracil; NA: not available.",
"     <br/>",
"     * Tamoxifen until the year 2000, when aromatase inhibitors became first choice in treatment for relapse or metastatic disease.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     History of diabetes mellitus, arterial hypertension, thyrotoxicosis, obstructive lung disease, alcoholism, or obesity.",
"     <br/>",
"     &Delta; Data not available for one metastasis because patients will always have more than one metastasis under these circumstances.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risk analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100:1058. Copyright &copy; 2008 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32621=[""].join("\n");
var outline_f31_54_32621=null;
var title_f31_54_32622="Traumatic ear pain in children";
var content_f31_54_32622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Traumatic diagnoses associated with ear pain in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TM: tympanic membrane.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32622=[""].join("\n");
var outline_f31_54_32622=null;
var title_f31_54_32623="Spleen aspirate 1A answer";
var content_f31_54_32623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blastomyces dermatitidis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papanicoleau stain of a fine-needle aspirate of the spleen (x400) shows the broad-based, thick-walled dividing yeast forms of Blastomyces dermatitidis. Identification of this organism may also be made by fungal culture on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hua Jiang, MD and Joyce Fingeroth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_54_32623=[""].join("\n");
var outline_f31_54_32623=null;
